I. Asthma and Asthma Therapy {#s1}
============================

A. Epidemiology, Pathology, and Pathophysiology of Asthma {#s2}
---------------------------------------------------------

Asthma is among the most prevalent noncommunicable diseases worldwide. According to the reports from Global Asthma Network and Global Initiative for Asthma (GINA), asthma affects 1%**--**18% of the population in different countries with a global prevalence of over 300 million people. In the United States, the estimated prevalence of asthma in 2010 was 8.4% of the population ([@B373]). Noticeably, this number has increased by 2.9% per year from 2001 to 2010. Asthma also affects about 6 million children between the ages of 0 and 17 in the United States, according to the Centers for Disease Control and Prevention. In fact, a recent review mentioned that asthma is the most common childhood noncommunicable disease ([@B96]). Because of the high prevalence and chronic nature, asthma brings a serious economic burden to the society. It was estimated that asthma was responsible for a total cost of \$81.9 billion dollars, including the medical costs and other indirect costs, in the United States for the year of 2013 ([@B451]). Although the mortality rate of asthma has decreased significantly in the past decades, it is still among the top leading causes of years lived with disability and burden of disease (Global Asthma Network Report 2018).

Our understanding of asthma has changed significantly in the past two decades [@B110]; [@B345]; [@B515]; [@B477]; [@B96]. Many studies have suggested a highly complex and heterogeneous nature of asthma. Therefore, asthma has been recognized and viewed more and more as a syndrome with a broad spectrum of distinct disease phenotypes and underlying pathophysiological mechanisms rather than one specific disorder ([@B157]; [@B643]; [@B653]; [@B477]). The most recent GINA report defines asthma as a heterogeneous disease, which is mainly characterized by chronic airway inflammation. Common symptoms for asthma include cough, chest tightness, wheezing, and shortness of breath. Asthma is associated with variable airflow limitation, airway hyperresponsiveness (AHR), and sometimes airway remodeling, which are also the major characteristics of chronic obstructive pulmonary disease (COPD) ([@B252]).

The definition of clinical phenotypes of asthma has attracted much attention in the past decade, which is still far from reaching a widely accepted consensus and remains controversial. Depending on various clinical, etiological, pathophysiological, or demographic characteristics, asthma can be clustered into different phenotypes ([@B224]; [@B570]; [@B643]; [@B80]). Commonly recognized phenotypes include allergic and nonallergic asthma (or atopic and nonatopic asthma), late-onset persistent asthma, and obesity-driven asthma. However, a specific asthma phenotypic trait may have multiple underlying disease mechanisms linked to different mechanistic pathways ([@B210]; [@B164]). Therefore, it has been suggested that disease endotypes, which are defined by specific pathophysiological mechanisms, may provide a better framework for asthma research ([@B5]; [@B488]; [@B473]; [@B362]). Biomarkers of each pathophysiological mechanism or mechanistic pathway could help to identify each endotype in the clinic, allowing for drugs or therapeutic methods that specifically target the underlying causative mechanism to be used for each endotype. The appropriate classification of asthma based on the phenotypes or endotypes is expected to provide a better understanding of asthma heterogeneity among patients so the therapeutic outcomes of specific treatment methods are more predictable. This will also facilitate the development of personalized and targeted therapies to fulfill currently unmet needs in the management and control of asthma, especially severe asthma.

Asthma has long been recognized as an inflammatory disease of the airways, particularly lower airways. Uncontrolled inflammation in the upper airways often leads to allergic rhinitis, which shares many common pathophysiological mechanisms with asthma ([@B372]). Intensive research effort has been focused on the immune pathways and immunologic processes that lead to various asthma phenotypes in the past two decades. A major breakthrough in the asthma immunology was the identification of the critical roles of a subset of CD4^+^ T cells, the T helper (T~H~)2 cells, and the immune responses mediated by T~H~2 cells in allergic asthma ([@B216]; [@B647]; [@B678]). T~H~2 cells can produce type 2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, which control and mediate type-2 immunity ([@B625]). Uncontrolled and chronic type 2 immunity in the airways leads to type 2 inflammation, which is the major driving force and the hallmark of allergic asthma ([@B372]; [@B164]). Recently, other types of adaptive immune cells, particularly the group 2 innate lymphoid cells (ILC2s), were also found to be important players in type 2 inflammation.

However, there is also a large body of evidence suggesting that many asthma patients, particularly patients with severe asthma, showed no or low characteristics of type 2 inflammation, indicating that additional pathophysiological mechanisms are involved ([@B644]; [@B282]; [@B210]; [@B650], [@B651]). From these various studies, asthma has been roughly classified as two endotypes, type 2 inflammation-high (type 2-high) and type 2-low. It was estimated that most children and half of adult patients with asthma are type 2 inflammation-related, whereas for patients with severe asthma type 2, inflammation-related phenotypes only represent 37% of the population ([@B651]; [@B345]; [@B338]). The type 2-low endotype represents an important and well-established severe asthma endotype, which is much less understood and much more diverse compared with the type 2-high endotype.

### 1. Type 2-High Endotype Pathophysiology {#s3}

Type 2 immunity and type 2 inflammation are well studied and understood. They are strongly linked to allergic or atopic pathologies in diseases such as asthma and are characterized by the production of type 2 cytokines, IL-4, IL-5, and IL-13, and high levels of IgE antibodies ([@B625]). Type 2 inflammation involves many types of innate and adaptive immune cells, including T~H~2 cells, ILC2s, specific B cells that produce IgE antibodies, eosinophils, basophils, and mast cells. Multiple pathways mediated by those cells work together through complex and heterogeneous interplay to result in different asthma phenotypes displaying characteristics of type 2 inflammation.

It is well accepted that the type 2 inflammation starts from the events in the airway epithelium. Allergens and other stimuli interact with airway epithelial cells, which then release a series of cytokines such as thymic stromal lymphopoietin (TSLP) and IL-25 and IL-33. These cytokine regulators can then lead to the generation of type 2 cytokines through activating multiple immune cells to drive the onset of type 2 inflammation. Activated and primed dendritic cells (DCs) during this process promote the differentiation of naive CD4^+^ T cells into T~H~2 cells, which are the major cell type producing type 2 cytokines ([@B476]). Two transcription factors, STAT6 and GATA3, are key to the activation of T~H~2 cells ([@B681]; [@B340]; [@B393]; [@B259]; [@B633]).

Another potent producer of type 2 cytokines are the recently discovered ILC2s ([@B167]; [@B418]; [@B440]; [@B500]; [@B628]). These innate lymphoid cells show some functional resemblance of T~H~2 cells. Although they do not have antigen receptors for T or B cells, they do express receptors for the cytokines produced by stimulated epithelial cells, TSLP, IL-25, and IL-33. Engagement of these cytokines with their receptors can lead the activation and recruitment of ILC2s, which in turn participate in the type 2 inflammation process by producing type 2 cytokines. Studies have demonstrated that they may produce even more IL-5 and IL-13 than T~H~2 cells under some circumstances ([@B101]). In addition, ILC2s may also contribute to the differentiation of naive CD4^+^ T cells into T~H~2 cells ([@B225]; [@B463]). The roles of ILC2s and T~H~2 cells in the production of type 2 cytokines and how they affect the functions of each other are still not fully understood. It is likely that ILC2s and T~H~2 cells may have different roles in different phenotypes of asthma. It is notable that ILC2s may show resistance to the steroid-induced suppression of type 2 cytokine production ([@B295]). Because steroid drugs are the mainstream drugs for reducing inflammation in asthma, a better understanding of the function of ILC2s in certain types of asthma patients with ILC2s as the dominant players in type 2 inflammation is important for developing appropriate personalized treatment plans.

Type 2 cytokines are the central regulatory molecules of type 2 inflammation ([@B164]; [@B654]). IL-4 can induce antibody class switching in B cells to result in IgE production. It also drives T cell differentiation to produce T~H~2 cells from naive CD4^+^ cells. IL-5 is a key regulator of the recruitment and development of eosinophils, another major cell type associated with type 2 inflammation. The activated eosinophils recruited to the airways can release a number of potent inflammatory mediators and disease-inducing molecules, including cytokines, cysteinyl leukotrienes (CysLT), and cytotoxic proteins. Eosinophilia in the airways causes eosinophilic asthma, which is an important type of asthma that is often severe. Other granulocytes such as mast cells and basophils also respond to IL-5. IL-13 is a primary effector that directly induces asthma symptoms. A well-characterized function of IL-13 is to drive the differentiation of airway epithelial cells into active goblet cells that produce mucins, a process called goblet cell metaplasia ([@B647]; [@B593]; [@B654]). Overproduction of mucins leads to the formation of thick mucus and subsequent airway clogging. In addition, IL-13 can also induce AHR and contribute to airway remodeling and even pulmonary fibrosis ([@B507]).

IgE antibodies produced by type 2 cytokine-induced B cells are another critical molecular controller of type 2-high asthma. In general, IgE antibodies are considered as the major characteristics of atopic diseases. In asthma, IgE antibodies can bind to the high-affinity IgE receptor Fc*ε*RI that is highly expressed on mast cells, basophils, and DCs. Engagement and cross-linking of IgEs to their receptor lead to the migration and degranulation of mast cells and basophils and the activation of DCs, which then results in the release of potent inflammatory molecules, including histamine, inflammatory lipid mediators, and chemokines ([@B345]). These molecules are directly associated with airway hypersensitivity. Activated DCs can promote the differentiation of CD4^+^ T cells, which may be important for the development of chronic airway inflammation ([@B346]). Basophils also have been shown to secrete IL-4, further amplifying type 2 inflammation ([@B450]; [@B408]; [@B313]).

### 2. Type 2-Low Endotype Pathophysiology {#s4}

The variations of type 2-low asthma and the underlying pathophysiological mechanisms are far less understood compared with the type 2-high asthma. It is highly likely that the type 2-low endotype may actually be comprised of several distinct endotypes, all of which are associated with normal levels of type 2 cytokines ([@B164]). Given the fact that less than half of severe asthma patients are associated with dominant type 2 inflammation, the pathophysiology of type 2-low asthma has attracted more and more research interest ([@B522]). However, to date it is still enigmatic and there is no effective treatment method that specifically targets type 2-low asthma.

One characteristic found in many type 2-low asthma patients is the high level of neutrophils instead of eosinophils. Neutrophilic inflammation is usually associated with high levels of T~H~1 and T~H~17 cells ([@B558]; [@B403]). However, the mechanisms underlying the recruitment and activation of these cells and how they contribute to asthma symptoms are not clear. One study suggested the involvement of the intracellular NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome in neutrophilic asthma ([@B565]). Increased levels of cytokines produced by T~H~17 cells including IL-17A, IL-17F, and IL-22 have also been found in neutrophilic asthma. However, the functional roles of these cytokines are controversial. IL-17A has been suggested to contribute to airway remodeling ([@B48]). Previous studies also suggested the involvement of other inflammatory mediators such as IL-8 and tumor necrosis factor-*α* in neutrophilic inflammation ([@B51]; [@B649]).

The mainstream anti-inflammatory steroid drugs are far less effective in reducing T~H~17 cytokines than reducing type 2 cytokines. Therefore, neutrophilic asthma driven by T~H~17 inflammatory mediators exhibits resistance to steroid therapies, which seems to be a common feature of type 2-low asthma. It is of paramount importance to identify different endotypes of type 2-low asthma and the underlying pathophysiological mechanisms to develop novel asthma therapies.

B. Current Treatment Methods {#s5}
----------------------------

The pharmacological options for treatment and management of asthma include inhaled corticosteroids (ICSs), oral corticosteroids, long-acting *β*~2~-agonists (LABAs), short-acting *β*~2~-agonists (SABAs), long-acting muscarinic antagonists (LAMAs), short-acting muscarinic antagonists (SAMAs), leukotriene modifiers, theophylline, cromolyn, and immune-modulating antibody drugs, which are well summarized in the GINA Report 2018 and the Lancet paper by [@B477]. Most of these medications fall into the following three main categories: 1) long-term control medications; 2) quick-relief medications; and 3) biologic agents ([Table 1](#T1){ref-type="table"}). Long-term control medications reduce airway inflammation that leads to chronic symptoms and include therapies such as ICSs, LABAs, LAMAs, leukotriene modifiers, theophylline, and cromolyn. Quick-relief medications quickly open constricted airways that limit breathing and include oral corticosteroids, SABAs, and SAMAs. In certain situations, biologic drugs are required, including the IgE antibody omalizumab and the anti-IL antibodies.

###### 

Overview of current asthma drugs

  Drug                                   Category                            Target                                     Mechanism of Action                                Medical Use                                            Examples
  -------------------------------------- ----------------------------------- ------------------------------------------ -------------------------------------------------- ------------------------------------------------------ ----------------------------------------------
  ICSs                                   Long-term control medications       Glucocorticoid receptors                   Suppression of airway inflammation                 Mild/Moderate persistent asthma                        Budesonide, beclomethasone, fluticasone
  LABAs                                  Long-term control medications       *β*~2~AR                                   Relaxation of bronchial smooth muscle              Moderate to severe asthma                              Salmeterol, formoterol, olodaterol
  LAMAs                                  Long-term control medications       MRs (functional selectivity for M3R)       Relaxation of bronchial smooth muscle              Uncontrolled asthma                                    Tiotropium, umeclidinium, glycopyrrolate
  LTRAs                                  Long-term control medications       CysLT receptor 1                           Antagonize actions of leukotrienes in the airway   Secondary option for mild/moderate persistent asthma   Montelukast, pranlukast, zafirlukast
  Other leukotriene modifier             Long-term control medications       5-LOX                                      Inhibit the formation of leukotrienes              Secondary option for mild/moderate persistent asthma   Zileuton
  Methylxanthines                        Long-term control medications       Phosphodiesterase 3, adenosine receptors   Relaxation of bronchial smooth muscle              Secondary option for mild/moderate persistent asthma   Theophylline
  Mast cell stabilizer                   Long-term control medications       Calcium-activated potassium channels       Inhibit the release of inflammatory mediators      Mild persistent asthma                                 Cromolyn
  Oral and intravenous corticosteroids   Quick-relief (rescue) medications   Glucocorticoid receptors                   Suppression of airway inflammation                 Severe asthma                                          Prednisolone, prednisone, methylprednisolone
  SABAs                                  Quick-relief (rescue) medications   *β*~2~AR                                   Relaxation of bronchial smooth muscle              Severe asthma                                          Albuterol, levalbuterol
  SAMAs                                  Quick-relief (rescue) medications   MRs (no selectivity for M3R)               Relaxation of bronchial smooth muscle              Acute asthma exacerbation                              Ipratropium, oxitropium
  Antibodies                             Biologic agents                     IgE and ILs                                Reducing inflammation by blocking IgE and ILs      Allergic and severe asthma                             Omalizumab, mepolizumab, dupilumab

### 1. Long-Term Control Medications {#s6}

#### a. Inhaled corticosteroids {#s7}

ICSs include beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, fluticasone furoate, mometasone furoate, and fluticasone propionate. These medications reduce AHR and control asthma symptoms through suppression of airway inflammation. Corticosteroids suppress inflammation mainly by acting on the glucocorticoid receptors to switch off multiple activated inflammatory genes that encode for cytokines, chemokines, adhesion molecules, inflammatory enzymes, and receptors, through reversing histone acetylation via the recruitment of histone deacetylase 2 ([@B33]). Corticosteroids can also switch on transcription of genes encoding *β*~2~-adrenergic receptors (*β*~2~AR), secretory leukocyte inhibitory protein, and mitogen-activated protein kinase (MAPK) phosphatase-1 ([@B33], [@B34]). These effects may contribute to the anti-inflammatory actions of corticosteroids. Inhaled corticosteroids are the most effective and safe medications for long-term asthma control with adjunct medications such as *β*~2~‐agonists ([@B107]).

#### b. Long-acting *β*~2~-agonists {#s8}

There are a number of LABAs used in the clinics, which include salmeterol, formoterol, vilanterol, and olodaterol. These medicines have much longer half-life profiles in binding to *β*~2~-adrenergic receptors within the bronchioles than short-acting *β*~2~-agonists, leading to a longer duration of effect ([@B631]). LABAs are recommended to be only used in the combination therapy with a corticosteroid, whereas LABAs provide symptomatic relief of asthma, and corticosteroids offer control of the underlying inflammatory pathology, thus reducing recurrence of exacerbations and overall mortality ([@B79]; [@B43]; [@B638]). Common combination therapy medicines include salmeterol/fluticasone, formoterol/budesonide, formoterol/mometasone, and vilanterol/fluticasone. Formoterol in combined use with budesonide is also used as a reliever medication because of its quick onset of action ([@B456]).

#### c. Long-acting muscarinic antagonists {#s9}

LAMAs include tiotropium, aclidinium, glycopyrronium, and umeclidinium. Muscarinic antagonists elicit their function by binding to muscarinic receptors (MRs) M1, M2, and M3 and blocking neuronal and non-neuronal signals of acetylcholine. Among them, M3 receptors are found on the airway smooth muscle cells, mucosal glands, and vascular endothelium along the airways. Blockage of these receptors leads to a decrease in bronchoconstriction, leading to the primary effects of LAMAs in asthma ([@B3]; [@B124]). These LAMAs dissociate more slowly from the M3 receptors than from the M2 receptors, exhibiting a functional selectivity. Tiotropium has received Food and Drug Administration approval for the treatment of asthma, whereas others have been used in the treatment of COPD and could be developed toward asthma drugs ([@B354]; [@B75]; [@B178]; [@B206]). LAMAs are used in combination with LABAs for increasing the efficacy over monotherapy ([@B526]). Commonly used medicines include tiotropium/olodaterol, aclidinium/formoterol, glycopyrronium/indacaterol, and umeclidinium/vilanterol.

#### d. Leukotriene modifiers and leukotriene receptor antagonists {#s10}

Currently used leukotriene modifiers include montelukast, zafirlukast, pranlukast, and zileuton. Among them, montelukast, zafirlukast, and pranlukast are leukotriene receptor antagonists (LTRAs) that target G protein**--**coupled receptors (GPCRs), whereas zileuton is an inhibitor of 5-lipoxygenase (5-LOX) that inhibits the formation of leukotrienes \[leukotriene B~4~ (LTB~4~), leukotriene C~4~ (LTC~4~), leukotriene D~4~ (LTD~4~), and leukotriene E~4~ (LTE~4~)\]. These medications work to antagonize the effects of proinflammatory leukotrienes or to decrease leukotriene production. This results in decreased inflammation and decreased hyperresponsiveness of the airways to immune challenges ([@B549]). Leukotriene modifiers can be used as alternatives to inhaled corticosteroids for mild to moderate asthma, or used in addition to inhaled corticosteroids for moderate asthma ([@B439]; [@B550]).

#### e. Theophylline {#s11}

The mechanism of action of theophylline in obstructive lung disease management is poorly understood. It may act as a nonselective inhibitor of phosphodiesterases (PDEs) and a nonspecific adenosine receptor antagonist, leading to the relaxation of smooth muscles of airways ([@B36]). It also has been shown to reduce airway inflammation likely by inhibiting PDE4 and activating histone deacetylase 2, which results in the switching off of activated inflammatory genes. It is an alternative medicine to inhaled corticosteroids for mild asthma ([@B384]). Theophylline can also be used in combination with inhaled corticosteroids to treat moderate to severe asthma ([@B384]).

#### f. Cromolyn {#s12}

Cromolyn is traditionally described as a mast cell stabilizer, yet its mechanism of action is not fully understood. It is known to inhibit calcium-activated potassium channels and thus may inhibit the exaggerated neuronal reflexes triggered by the stimulation of irritant receptors on sensory nerve endings in exercise-induced asthma (EIA). It also inhibits the release of preformed cytokines from several types of inflammatory cells in allergen-induced asthma ([@B349]; [@B667]). Cromolyn therapy has been largely replaced by LTRAs.

### 2. Quick-Relief (Rescue) Medications {#s13}

#### a. Oral and intravenous corticosteroids {#s14}

Oral and intravenous corticosteroids include prednisolone, prednisone, and methylprednisolone. These medications are used on a short-term basis to relieve airway inflammation in severe asthma, as they can cause serious side effects when used long-term [@B439]; [@B4]; [@B557].

#### b. Short-acting *β*~2~-agonists {#s15}

SABAs used in North America include albuterol and levalbuterol. Albuterol and levalbuterol are both *β*~2~-adrenergic receptor agonists. Albuterol became commercially available in 1969 and is still used as a highly effective rescue therapy today ([@B496]). These medicines function by a similar mechanism of action as LABAs, but with a shorter duration of action. Other SABAs such as terbutaline and procaterol are also used in regions such as Scandinavia and Japan.

#### c. Short-acting muscarinic antagonists {#s16}

The commonly used SAMAs are ipratropium and oxitropium. They are derivatives of the nonspecific muscarinic antagonist atropine, which acts by inhibiting the signaling of MRs to relax smooth muscles ([@B4]; [@B496]). They can also be used in combination with SABAs, such as albuterol or fenoterol, for increasing the efficacy over monotherapy ([@B67]; [@B447]; [@B149]).

### 3. Biologic Agents {#s17}

Biologic agents as therapies for asthma were developed rather recently. They target IgE and type 2 cytokines, which can provide additional therapeutic benefits by further reducing type 2 inflammation in asthma. Biologic drugs are usually used as a phenotype-selective treatment method, and our understanding of asthma endotyping helps to identify optimal biologics as targeted therapy ([@B483]; [@B589]).

Omalizumab is a human monoclonal antibody. It works by directly binding and blocking IgE, which is responsible for many allergy symptoms, thus reducing the ability of IgE to induce a T~H~2 immune response, including eosinophilia and mast cell activation ([@B100]; [@B131]; [@B132]). Omalizumab may be particularly useful for patients who have allergies and severe asthma ([@B439]; [@B132]).

Anti-IL antibodies include mepolizumab, reslizumab, benralizumab, and dupilumab ([@B118]; [@B64]; [@B171]). These medications are used as add-on therapies for adults with severe asthma and eosinophilia. Mepolizumab, reslizumab, and benralizumab bind to the IL-5 receptor, thus inhibiting its signal to proliferate eosinophils in bone marrow. Dupilumab binds to the IL-4 receptor, modulating signaling of both the IL-4 and IL-13 pathways ([@B89]).

C. Inhalation Therapy {#s18}
---------------------

Corticosteroids have been administered for over 50 years and are used to prevent airway inflammation, decrease mucus production, and reduce airway hypersensitivity ([@B34]). The most commonly prescribed medication for asthma management is an inhaled corticosteroid (ICS) paired with a bronchodilator ([@B34]; [@B564]; [@B206]). Typically the bronchodilator is a SABA or LABA; however, several anticholinergics have been recently approved for asthma management as stand-alone or add-on therapies. Inhaled therapies are administered by one of three common types of inhalation devices, with the metered dose inhaler (MDI) being the most common. MDIs use a chemical propellant to push the medication out of the inhaler. MDIs often come with what is called a spacer. The spacer helps a person to better coordinate inhalation with release of the drug from the canister and insures that more drug is properly delivered. Dry powdered inhalers do not use a chemical propellant, but require fast and accurate inhalation to ensure that most of the drug enters the lungs. The last type is a nebulizer, which requires the use of a mask that fits over the mouth or nose and requires the use of oxygen or air under pressure to deliver the drug in a fine mist. Nebulizers are the most effective form of drug delivery and especially useful for young children and those who are unable to coordinate inhalation with drug release. However, they are the most time consuming as it can take upward of 15 minutes to deliver each dose of drug.

D. Preclinical Models of Asthma {#s19}
-------------------------------

Numerous animal models have been used to decipher various aspects of asthma pathophysiology, identify novel therapeutic targets, and test the efficacy of emerging therapies. Reports using models of *Drosophila melanogaster* ([@B523]), canines ([@B466]; [@B687]), felines ([@B449]), rats ([@B335]), equines ([@B245]), sheep ([@B687]; [@B541]), guinea pigs ([@B81]), nonhuman primates ([@B113]), and mice ([@B687]; [@B446]; [@B98]; [@B19]) can be found in the literature. Although felines and equines spontaneously display asthma-like symptoms, 1% of cats develop eosinophilic bronchitis ([@B467]; [@B19]), and horses develop heaves resulting from moldy hay ([@B38]); they are not financially viable models for asthma research. Despite the physiologic compatibility of cats and horses, as well as guinea pigs, and nonhuman primates compared with mice, the diminished feasibility based on costs, transgenic resources, and other factors has made mice the gold standard for models of asthma ([@B687]; [@B446]; [@B98]; [@B19]).

Although mice are the predominant species used for preclinical models of asthma, there are some distinct physiologic differences and caveats that should be realized. The most obvious is that mice are quadrupeds and the distribution of ventilation is strongly influenced by gravity, which is an important pathophysiological feature of human asthma. Airway branching in mice is also different than humans. Mice only have six to eight distinct branches, whereas humans have 23 that are symmetrical and dichotomous. Branching in mice and other nonprimates is monopodial, in which one daughter branch may be larger than the other ([@B203]). Compared with humans, mice have large caliber airways for their respective lung size. These differences are likely to affect ventilation and aerosol distribution, thus confounding AHR studies and the implications of airway obstruction and structural changes, as well as the effects of nonaerosolized treatments ([@B98]).

As mice do not spontaneously develop allergic airway disease, models have been developed that include sensitization with an allergen, often accompanied by an adjuvant, followed by multiple challenges with allergen alone. A common timeline involves sensitization in the first 2 weeks, followed by challenge at multiple time points during the following weeks for acute studies and challenge over the course of 1--3 months for chronic models. Much like the choice of species, other factors including time and expense have resulted in the majority of studies being designed using acute models, which does not best reflect what occurs clinically ([@B446]; [@B19]). Chronic models have been developed to better replicate structural changes that include subepithelial and airway wall fibrosis, goblet cell hyperplasia, smooth muscle thickening, and increased vascular permeability ([@B446]; [@B19]). Chronic inflammation and structural changes have functional consequences that contribute to asthma symptoms and reflect the clinical phenotype, as most result in airway remodeling and persistent AHR. However, there are also concerns regarding chronic models, as it has been observed that immune tolerance may develop ([@B19]; [@B556]). Additionally, mouse inflammation is not restricted to the conducting airways as it is in humans, and both lung parenchymal and vascular inflammation and remodeling are observed in mice as well ([@B446]). There is also a disparity in the recruitment of mast cells to airway walls and epithelium, which likely speaks to the paucity of mast cells in mice ([@B358]), making the role of the prostaglandin (PG)D~2~ receptor, DP2, or therapies directed toward them challenging to study in mice.

Mouse strain, allergen, route of administration for sensitization and challenge, and timing are all aspects of a model that will influence the inflammatory response. BALB/c mice are often used as they present a T~H~2-biased response; however, C57BL/6 and A/J mouse models have also been developed. For instance, C57BL/6 are a common background for transgenic mice, and this strain is also used in high-fat--diet asthma models as male C57BL/6 more readily develop a type 2 diabetic phenotype ([@B314]). A/J mice have been used in several studies modeling steroid resistance ([@B555]).

Ovalbumin (OVA) challenge has been the mainstay allergen of the allergic airway disease model. Mice are sensitized with OVA and Al(OH)~3~ adjuvant, most often via intraperitoneal injection within the first 2 weeks, followed by a period of challenge via oral pharyngeal (intratracheal), intranasal, or aerosolized delivery ([@B446]; [@B98]; [@B19]). The use of OVA to induce allergic airway disease has been heavily criticized as intraperitoneal administration is not the natural route of allergen exposure, and OVA is not a clinically relevant allergen ([@B98]). More recently, models have developed in which house dust mite (HDM), cockroach extract (*Blatella germanica*, Bl g2), ragweed, *Aspergillus fumigatus* (fungi causing allergic rhinitis), and the parasite *Ascaris lumbricoids* have been used ([@B687]; [@B446]; [@B98]; [@B240]; [@B19]). Studies indicate that 50% to 85% of asthmatics are allergic to HDM ([@B442]), and, although HDM is typically administered without an adjuvant during sensitization, it must be noted that endotoxin levels can vary between lots and sometimes be quite high. This must be taken into consideration as the lipopolysaccharide present will promote an acute inflammatory response. Along with lipopolysaccharide, HDM protein, fecal matter, and chitin found in the HDM extract induces TSLP, granulocyte-macrophage colony-stimulating factor, IL-25, and IL-33 via TLR4 activation on airway epithelial cells ([@B228]).

Studies using gene knockout mice combined with OVA challenge have helped to establish the roles of muscarinic acetylcholine receptors in asthma ([@B317]). A number of studies used OVA-challenged mice and guinea pigs to test the effects of tiotropium, a classic LAMA drug, in the airway inflammation, which suggested a combined therapy of tiotropium and a steroid in the treatment of asthma ([@B70]; [@B300]; [@B316]). OVA-challenged mice models have also been used to examine the role of CysLT receptors and leukotriene receptor antagonists in airway inflammation and modeling ([@B244]; [@B267]). Interestingly, a few studies using gene knockout mice with OVA or leukotriene E~4~ challenge have predicted additional leukotriene receptors that may be critical new drug targets for asthma, which are still under investigation ([@B475]; [@B299]; [@B611]).

Utilization of preclinical models of asthma has been invaluable to the characterization of the T~H~2-high atopic phenotype, the discovery of novel targets, and determination of drug efficacy, despite the many caveats described. An in-depth understanding of the mechanisms underlying each asthma phenotype remains the ultimate path forward in personalized medicine, and mouse and other animal models of asthma can be tailored to specific aspects that contribute to these phenotypes. For instance, animal models provide an opportunity to study parameters aside from allergens that contribute to the asthma pathophysiology, including obesity, age, steroid resistance, aspirin sensitivity, and asthma severity. Despite their utility, animal model research should not directly lead to clinical conclusions, but inform us of important targets for therapy and novel pathways of interest. Models should be paired with studies involving clinical samples, such as those conducted using bronchoscopy-derived primary airway epithelial cells at the air--liquid interface, precision-cut lung slices, or the reprogramming of patient-derived pluripotent stem cells and fibroblasts to epithelial and smooth muscle cells ([@B422]). These types of translational studies will provide a more comprehensive understanding of the complex interactions of inflammation, bronchodilation, and AHR that present as asthma.

E. G Protein--Coupled Receptors as Important Drug Targets in Asthma {#s20}
-------------------------------------------------------------------

GPCRs constitute the largest family of drug targets in humans. It was estimated that over 33% of currently used small-molecule drugs target GPCRs ([@B540]). This is due to many druggable properties of GPCRs. First, GPCRs are key players that sense extracellular signaling molecules on cell surfaces. They are involved in nearly every aspect of in vivo physiologic processes. Almost every physiologic pathway can be dampened or enhanced by pharmacologically manipulating certain GPCRs. Second, most native and endogenous GPCR ligands are small-molecule chemicals and peptides, and many GPCR-targeting drugs were developed based on natural molecules. Thus, there are many natural chemical templates for designing novel small-molecule drugs. Lastly, the ligand-binding sites are located at the extracellular regions of GPCRs, which can be easily accessed by drugs.

Many currently used asthma medications target GPCRs. Studies in the past several decades have proven the important roles of a number of GPCRs, including *β*~2~-adrenergic receptor, muscarinic acetylcholine receptors, leukotriene and PG receptors, chemokine receptors, and adenosine receptors in asthma. A large number of clinical trials have provided critical insights into the significance of GPCR-targeting therapies in the treatment of asthma. Also, the progress in GPCR structural biology in the past decade has allowed us to understand the actions of many GPCR-targeting drugs on a molecular level ([@B239]). In this review, we will focus on the GPCRs as existing and potential drug targets for asthma. We hope to summarize our current understanding of their physiology and pharmacology and discuss structural insights into drug action.

II. *β*~2~-Adrenergic Receptor and *β*~2~-Agonists {#s21}
==================================================

A. Pathophysiological Roles and Signaling of the *β*~2~-Adrenergic Receptor in Asthma {#s22}
-------------------------------------------------------------------------------------

The *β*~2~AR is a member of the adrenergic receptor (adrenoceptor) family, which is comprised of two major *α* types and three *β* types of receptors. These receptors are targets of catecholamine neurotransmitters, including epinephrine and norepinephrine (adrenaline and noradrenaline). Catecholamine-signaling molecules act on these receptors to stimulate the sympathetic nervous system to mediate classic fight-or-flight responses. Members of this family are all important drug targets. *β*~2~AR is highly expressed in airway smooth muscle (ASM) cells and bronchial epithelial cells. *β*~2~-agonists have been used as bronchodilators in the treatment of various respiratory diseases, including asthma, for decades.

Historically, the *β*~2~AR has been the model receptor for GPCR-related research. Hamster *β*~2~AR was the first GPCR to be cloned in the late 20th century ([@B146]; [@B357]). Results from studies of the *β*~2~AR have greatly advanced our understanding of GPCR pharmacology and signaling. In the classic scenario of receptor signaling, the *β*~2~AR can be activated by endogenous agonists, epinephrine, and norepinephrine, or synthetic agonists, such as *β*~2~-agonist drugs, to couple to and further activate the stimulatory G~s~ protein, resulting in the release of the *α* subunit of G~s~ (G*α*~s~). The G*α*~s~ then binds to and activates adenylyl cyclase, which in turn catalyzes the conversion of ATP to cAMP.

cAMP is a second-messenger molecule that can induce cAMP-dependent signaling pathways. One of the well-characterized cAMP effectors is protein kinase A (PKA). PKA was the first cAMP effector to be discovered and is a major effector in asthma airway pathophysiology ([@B610]; [@B234]; [@B44]), although the roles of PKA in mediating *β*~2~-agonist**--**mediated relaxation of airways are still controversial. [@B577] showed that the suppression of acetylcholine-induced contractions by *β*~2~-agonists is independent of PKA. Another study by [@B417] suggested that *β*~2~-agonist--mediated relaxation of airways is PKA dependent. It has been established that PKA phosphorylates many substrates in the ASM cells, such as myosin light chain kinase, inositol triphosphate receptors, calcium-gated potassium channels, and receptors that mediate G~q~ signaling pathways. The consequences of these PKA-mediated events include the downregulation of intracellular calcium levels and the reduction of sensitivity of contractile proteins to calcium, which overall counteract mechanisms that lead to ASM contraction ([@B484]; [@B631]). However, it is likely that different mechanisms are involved in promoting the relaxation of airways and protecting relaxed airways against contractile stimuli. In addition, PKA has been demonstrated to mediate the antimitogenic effects of *β*~2~-agonists ([@B663]).

Another cAMP effector involved in airway physiology are Epac proteins, the exchange factors directly activated by cAMP ([@B527]). Epac 1 and 2 have been characterized to be the cAMP-dependent nucleotide exchange factors for Rap proteins and several others of the RAS-like small GTPase family. As novel cAMP sensors, Epac proteins regulate diverse cellular processes. The involvement of Epac proteins in asthma remains elusive. Some studies suggest that cAMP-mediated signaling through Epac contributes to the relaxation of contracted smooth muscle ([@B686]). Further investigation into the roles of Epac proteins in the physiologic function of *β*~2~-agonists will help to determine whether they are valid therapeutic targets for asthma.

Agonist-activated *β*~2~AR can be phosphorylated by many kinases, including PKA and GPCR kinases, which leads to the recruitment of *β*-arrestins and the initiation of receptor internalization. *β*-arrestins were originally considered to be the terminators of G protein--dependent signaling because they can competitively block the coupling of G proteins to GPCRs. In the late 1990s and early 2000s, [@B377], [@B560], and [@B559] provided evidence suggesting that *β*~2~AR could also signal through *β*-arrestins, and the *β*-arrestin--mediated pathways were G protein--independent. This has led to the establishment of concept of biased signaling or functional selectivity that applies to many other GPCRs. Biased signaling implies that different agonists may act on the same receptor, but recruit and activate distinct signaling partners, including G proteins and *β*-arrestins, to induce disparate signaling events ([@B139]; [@B573]).

Although the signaling of *β*~2~AR can relax the airways to relieve asthma symptoms, it can also promote inflammation and other detrimental effects in asthma. [@B321] showed that LABAs such as salmeterol could promote the activation of STAT6, an important transcription factor involved in the activation of T~H~2 cells, leading to the enhancement of asthma-like allergic airway disease in mice. Consistently, using *β*~2~AR^−/−^ mice, another study demonstrated that the signaling of *β*~2~AR in airway epithelial cells could lead to AHR and promote eosinophilic inflammation and mucous cell metaplasia ([@B444]). The same study also suggested the involvement of *β*-arrestins, in particular *β*-arrestin-2, in the *β*~2~AR-induced inflammation.

*β*-arrestins mediate largely unwanted effects of *β*~2~-agonists in the treatment of asthma. It is well known that long-term treatment with *β*~2~-agonists can lead to desensitization or tolerance, which may partly stem from the *β*-arrestin--mediated internalization and degradation of *β*~2~AR ([@B623]; [@B486]). In addition, *β*-arrestins, especially *β*-arrestin-2, have been shown to constrain *β*~2~-agonist--induced relaxation of ASM, which is G protein--dependent ([@B137]). Previous studies from Bond, Walker, and colleagues ([@B630]; [@B254]; [@B486]), particularly those based on *β*-arrestin-2^−/−^ mice, suggested that *β*-arrestin--dependent signaling promotes inflammation in the airways. In fact, *β*-arrestin--dependent signaling pathways induced by GPCRs expressed in the airway cells have been shown to contribute significantly to the development of asthma, which may involve not only *β*~2~AR, but also other GPCRs ([@B630]; [@B254]; [@B629]).

Besides airway cells, B cells ([@B537]) and several innate immune cells, including eosinophils ([@B675]) and mast cells ([@B108]), also express *β*~2~AR. The expression of *β*~2~AR in different T cell subtypes is contentious ([@B538]; [@B374]). The signaling of *β*~2~AR in the immune cells in the context of asthma and airway inflammation is less studied and defined. The role of *β*~2~AR signaling in innate immune cells seems to be anti-inflammatory. A SABA, albuterol, has been shown to reduce the secretion of LTC~4~ and eosinophil peroxidase by eosinophils ([@B423]). *β*~2~AR signaling and *β*~2~-agonists could also inhibit the release of histamine and other inflammatory mediators from human mast cells in lung and peripheral blood ([@B108]; [@B635]; [@B548]). In contrast, *β*~2~AR signaling in B cells has been suggested to promote IgE production ([@B121]; [@B304]), which is dependent on the activation of p38 MAPK, but not PKA ([@B498]; [@B400]), thus contributing to airway inflammation. In addition, [@B375] showed that a nonselective *β*-agonist can enhance the survival and accumulation of T~H~2 cells through PKA-independent mechanisms.

Because of the proinflammatory side effects of *β*~2~AR signaling, even though antagonists or inverse agonists of *β*~2~AR such as commonly used *β*-blockers were contraindicated in the past in asthma because of their potential effects of worsening bronchospasm ([@B462]), they may provide therapeutic benefits in asthma to reduce inflammation and AHR and/or resensitize *β*~2~AR ([@B143]). Several studies from Bond and colleagues ([@B78]; [@B293]) showed the beneficial effects of certain *β*-blockers in murine models of asthma. The biased signaling properties of *β*-blockers may play important roles in this context because several *β*-blockers such as carvedilol have been shown to induce *β*-arrestin--dependent signaling and MAPK activation, which promote inflammation ([@B189]; [@B648]; [@B598]). However, the different results from clinical studies using two *β*-blockers, nadolol ([@B233], [@B232]) and propranolol ([@B563]), have spurred a large debate over whether functionally selective *β*-blockers represent a potential therapeutic method for asthma ([@B305], [@B306]; [@B60]; [@B364], [@B365]; [@B485]). The safety of using *β*~2~AR-targeting *β*-blockers in asthma patients is also controversial and needs to be further investigated ([@B14]; [@B416]). More clinical investigation and data are needed to clarify if and under what conditions *β*-blockers do provide therapeutic benefits over potential risks in the treatment of asthma.

B. Currently Used *β*~2~-Agonist Drugs and Their Pharmacological Properties {#s23}
---------------------------------------------------------------------------

More than 100 years ago, researchers already found that the endogenous ligand of *β*~2~AR, epinephrine, could be injected into patients to acutely treat an asthma attack. In the mid-20th century, studies suggested that inhalation of epinephrine also worked well in releasing bronchoconstriction ([@B406]). This has led to the wide use of inhalers for delivering *β*~2~-agonists as bronchodilators for treating asthma and COPD. In the past eight decades, a large number of *β*~2~-agonists have been developed and approved for this. The first synthetic *β*~2~-agonist, isoproterenol, was introduced to the clinic in the 1940s. Further medicinal chemical studies led to the development of a number of *β*~2~-agonists in the 1960s and 1970s as the first generation of *β*~2~-agonist drugs, some of which are still used today as the mainstream *β*~2~-agonist drugs such as salbutamol, formoterol, and salmeterol. New *β*~2~-agonists are still being developed for the asthma market, and a detailed discussion of the clinical use of *β*~2~-agonists can be found in a recent review article ([@B53]).

Based on their duration of action, traditional *β*~2~-agonists were classified into two groups: short-acting *β*~2~-agonists (SABAs), such as isoproterenol, salbutamol, and terbutaline, and LABAs, such as salmeterol and formoterol. SABAs provide almost instant relief of asthma symptoms and are used as rescue medicines for treating acute asthma attacks. However, their bronchodilatory effects usually last for only a few hours, thus limiting their use on a regular basis. LABAs exhibit a long duration of action for more than 12 hours and are commonly used with ICS for the long-term management of asthma symptoms. In the past decade, new agents have been developed as ultra-LABAs, extending the duration of action to over 24 hours for the COPD market. These potent Food and Drug Administration (FDA)--approved bronchodilators include indacaterol, olodaterol, and vilanterol. The use of ultra-LABAs has led to improved clinical outcomes as the once-daily dosing regimen has likely improved medication adherence ([@B412]). Whether ultra-LABAs can provide similar clinical benefits to asthma patients is still under investigation.

A major aspect of the research efforts that have gone into the development of new *β*~2~-agonists is focused on improving duration of action. However, other pharmacological properties of LABAs and ultra-LABAs also affect their clinical outcomes. One of them is the receptor subtype selectivity, which may be associated with the cardiac side effects of *β*~2~-agonists ([@B535]). Three subtypes of *β*-adrenergic receptors have been characterized to date, *β*~1~-adrenergic receptor (*β*~1~AR), *β*~2~AR, and *β*~3~-adrenergic receptor (*β*~3~AR). *β*~2~AR is the dominant *β*-adrenergic receptor expressed in the airways, and *β*~1~AR and *β*~2~AR are both highly expressed in cardiac tissues with an estimated ratio of 3:1 ([@B66]). *β*~3~AR is much less studied, but it is believed to be mainly located in adipose tissues to regulate lipolysis and energy expenditure. Overstimulation of *β*~1~AR and *β*~2~AR in the heart can induce adverse cardiovascular events. Also, due to the sequence similarity between *β*~1~AR and *β*~2~AR and the conservation of the ligand-binding sites, most of the ligands acting on these two receptors do not exhibit high receptor subtype selectivity, making cardiovascular side effects a major concern ([@B23], [@B24]). Indeed, a meta-analysis suggested that many *β*~2~-agonists were associated with an increased risk of adverse cardiovascular events, leading to myocardial infarction, arrhythmias, ischemia, and heart failure through the stimulation of *β*-adrenergic receptors ([@B93]). In contrast, because *β*~1~AR is expressed with a much higher level in the heart than it of *β*~2~AR, highly selective *β*~2~AR-agonists may be associated with a lower cardiac toxicity compared with nonselective *β*~2~-agonists. This was confirmed by clinical studies on a long and widely used LABA, salmeterol, which exhibits over 1000-fold selectivity over the *β*~1~AR ([@B175]). In these studies, regular use of salmeterol minimally increased the risk of adverse cardiovascular events compared with placebo ([@B175]). Another small-scale clinical study examined the cardiac effects of salmeterol and another LABA, formoterol ([@B92]). Compared with salmeterol, formoterol has a much lower selectivity for the *β*~2~AR ([@B24]), and this study showed that formoterol used at a dosage of 24 *µ*g/day was associated with a higher heart rate than 50 *µ*g/day salmeterol.

The lower receptor subtype selectivity is not the only reason for the stronger cardiac effects associated with formoterol compared with salmeterol. Another pharmacological property of *β*~2~-agonists that may affect their therapeutic effects is efficacy. Data from biophysical studies on purified *β*~2~AR showed that salmeterol is less efficacious in inducing a fully active conformation of the receptor for G~s~ coupling compared with full agonists, epinephrine and isoproterenol, indicating a partial agonism of salmeterol in this minimized, receptor-only system ([@B211]; [@B392]). Consistently, it has been shown that in the heterologous expression systems and native cells formoterol is a full agonist of *β*~2~AR with a similar efficacy as isoproterenol, and salmeterol is a partial agonist with lower efficacy at saturating concentrations in the context of cellular G~s~ signaling and cAMP accumulation ([@B401]; [@B61]). Another study measuring relaxation of isolated human bronchi also showed that salmeterol is a weaker *β*~2~-agonist than formoterol ([@B438]). Clinical studies confirmed the partial agonism of salmeterol in reducing bronchoconstriction in asthma patients compared with formoterol ([@B471], [@B470]). In another clinical study comparing the cardiac effects of formoterol and salmeterol, the authors suggested that the lower efficacy of salmeterol contributes to its decreased cardiac effects ([@B92]). It was proposed that partial agonists in general might provide more benefits for treating chronic diseases by minimizing the overstimulation and desensitization of cell surface receptors compared with full agonists ([@B684]).

It has to be pointed out that several studies also demonstrated a maximal functional efficacy of salmeterol in systems in which there is a high receptor density or an efficient coupling to adenylyl cyclase ([@B120]; [@B662]). Such an inconsistency suggests the importance of experimental contexts in measuring ligand efficacy. This is not just for *β*~2~AR, but also for many other GPCRs. The traditional concept of ligand efficacy may need to be revisited given the high complexity and heterogeneity of GPCR signaling systems revealed by recent research progress. Nevertheless, salmeterol is still considered as a potent bronchodilator with satisfactory clinical efficacy, as evidenced by its wide use ([@B95]). Similarly, a SABA, salbutamol, is also a partial agonist of *β*~2~AR that is widely used for treating asthma attacks.

The concept of biased signaling is relatively new, but is another important aspect that may contribute to *β*~2~-agonist mechanism of action, although controversies still exist. The biased property of *β*~2~-agonists has been extensively studied in heterologous systems. [@B616] showed that several *β*~2~-agonists including salbutamol and salmeterol exhibit significant signaling bias toward extracellular signal-regulated kinase 1/2 pathway over cAMP accumulation, calcium mobilization, and receptor endocytosis relative to isoproterenol in HEK293 cells. Studies from Clark and others ([@B84]; [@B414]; [@B198]; [@B392]) demonstrated that salmeterol behaved as a biased ligand against *β*-arrestin recruitment and receptor desensitization relative to formoterol or epinephrine in assays using transfected cells, although another study suggested similar efficacies of salmeterol for G~s~-dependent signaling and *β*-arrestin--associated signaling ([@B151]). [@B366] tested 40 *β*~2~-agonists in transfected HEK293 cells and reported a bias toward G~s~ signaling over *β*-arrestin recruitment for many agonists, including salmeterol and fenoterol, relative to isoproterenol and formoterol. However, whether commonly used *β*~2~-agonists such as salmeterol exhibit functional bias in native systems still needs further investigation.

Intuitively, poor desensitization of *β*~2~AR may contribute to the prolonged therapeutic effects of *β*~2~-agonists. Early studies suggested that partial agonists with low efficacy such as salmeterol cause less receptor desensitization compared with full agonists such as formoterol ([@B281], [@B280]). However, later studies provided evidence suggesting a much more complex scenario, in which the pattern and mechanism of receptor desensitization are agonist--specific ([@B156]; [@B120]). Clinical studies on the receptor desensitization induced by *β*~2~-agonists generated contradictory results, which were reviewed in a commentary by [@B99].

It needs to be emphasized that the use of *β*~2~-agonists alone can lead to serious detrimental effects ([@B112]). Historically, long-term overuse of isoproterenol alone as a SABA was linked to increased asthma mortality in some countries in the mid 20th century ([@B269]). A meta-analysis also suggested an increased risk of asthma mortality associated with salmeterol monotherapy ([@B638]). The same analysis also suggested that concomitant use of ICS could mitigate such risk. The underlying mechanism is still not entirely understood. Considering the fact that ICS reduces lung inflammation, it is possible that the inflammatory effects of *β*~2~AR signaling are the major determinant for the increased risk of asthma mortality associated with chronic *β*~2~-agonist therapy. Indeed, *β*~2~-agonists have been shown to induce inflammatory mediators in airway epithelial cells, which may be through G~s~ signaling ([@B158]; [@B521]). A recent study analyzed gene expression changes caused by *β*~2~-agonists and showed that an ultra-LABA, indacaterol, could upregulate many genes encoding proinflammatory proteins, most likely through the canonical cAMP/PKA signaling pathway ([@B662]). As discussed before, *β*-arrestin signaling pathways downstream *β*~2~AR activation also largely promote inflammation. Interestingly, in contrast to the proinflammatory roles, a number of studies from Newton and colleagues ([@bib689],[@bib690]; [@bib691]) showed that *β*~2~-agonists could enhance the anti-inflammatory action of glucocorticoids through the cAMP/PKA pathway. As required by the FDA, drugs that contain both a LABA and ICS were evaluated in large clinical trials for the risk of serious asthma outcomes, and the results supported a high safety profile with minimal side effects for such combined therapy ([@B53]). Therefore, nearly all treatment guidelines recommend that chronic use of LABAs should always be combined with an ICS.

C. Structural Insights into Drug Action {#s24}
---------------------------------------

The *β*~2~AR has served as a model receptor for GPCR-related studies for more than three decades. There is extensive experimental data providing detailed molecular insights into the activation and signaling of the receptor and the action of various *β*~2~-agonists. Intensive research efforts have been devoted to solving high-resolution structures of *β*~2~AR through X-ray crystallography approaches, which has led to the deposition of 22 structures in the Protein Data Bank (PDB) ([Table 2](#T2){ref-type="table"}). These structures revealed inactive and active conformational states of *β*~2~AR and the binding sites for a variety of antagonists and agonists.

###### 

Structures of human *β*~2~AR bound to various ligands

  PDB ID[*^a^*](#tfn1){ref-type="table-fn"}   Ligand                                             Efficacy                                    Fusion Partner[*^b^*](#tfn2){ref-type="table-fn"}   Binding Partner     Resolution (Å)   References
  ------------------------------------------- -------------------------------------------------- ------------------------------------------- --------------------------------------------------- ------------------- ---------------- ------------------
  2RH1                                        Carazolol                                          Inverse agonist                             T4 lysozyme (T4L) in ICL3                           None                2.40             [@B105]; [@B528]
  2R4R                                        Carazolol                                          Inverse agonist                             None                                                Fab5                3.40             [@B511]
  2R4S                                        Carazolol                                          Inverse agonist                             None                                                Fab5                3.40             [@B511]
  3D4S                                        Timolol                                            Inverse agonist                             T4L in ICL3                                         None                2.80             [@B235]
  3KJ6                                        Carazolol                                          Inverse agonist                             None                                                Fab5                3.40             [@B59]
  3NY8                                        ICI 118551                                         Inverse agonist                             T4L in ICL3                                         None                2.84             [@B626]
  3NY9                                        Compound 2a[*^c^*](#tfn3){ref-type="table-fn"}     Inverse agonist                             T4L in ICL3                                         None                2.84             [@B626]
  3NYA                                        Alprenolol                                         Antagonist                                  T4L in ICL3                                         None                3.16             [@B626]
  4GBR                                        Carazolol                                          Inverse agonist                             N-terminal T4L                                      None                3.99             [@B688]
  5D5A                                        Carazolol                                          Inverse agonist                             T4L in ICL3                                         None                2.48             [@B261]
  5D5B                                        Carazolol                                          Inverse agonist                             T4L in ICL3                                         None                3.80             [@B261]
  5JQH                                        Carazolol                                          Inverse agonist                             N-terminal T4L                                      Nanobody Nb60       3.20             [@B578]
  5D5B                                        Carazolol                                          Inverse agonist                             T4L in ICL3                                         None                3.20             [@B380]
  5X7D                                        Carazolol and intracellular antagonist Cmpd-15PA   Inverse agonist and allosteric antagonist   T4L in ICL3                                         None                2.70             [@B371]
  3PDS                                        FAUC50                                             Covalent agonist                            T4L in ICL3                                         None                3.50             [@B529]
  3P0G                                        BI-167107                                          Full agonist                                None                                                Nanobody Nb80       3.50             [@B510]
  3SN6                                        BI-167107                                          Full agonist                                N-terminal T4L                                      G~s~ heterotrimer   3.20             [@B512]
  4LDE                                        BI-167107                                          Full agonist                                N-terminal T4L                                      Nanobody Nb6B9      2.79             [@B520]
  4LDL                                        Hydroxybenzyl isoproterenol                        Full agonist                                N-terminal T4L                                      Nanobody Nb6B9      3.10             [@B520]
  4LDO                                        Adrenaline (epinephrine)                           Full agonist                                N-terminal T4L                                      Nanobody Nb6B9      3.20             [@B520]
  4QKX                                        Compound 2b^*c*^                                   Covalent agonist                            N-terminal T4L                                      Nanobody Nb6B9      3.30             [@B640]
  6MXT                                        Salmeterol                                         Partial agonist                             N-terminal T4L                                      Nanobody Nb71       2.96             [@B392]

PDB, <https://www.rcsb.org/>.

Inserting a small protein into GPCRs either at the ICL3 or at the N-terminal ends has been widely used to facilitate crystallization.

Compound 2a and compound 2b are unrelated. They were both named "compound 2" in the literature. Here we use 2a and 2b to avoid confusion.

ICL3, intracellular loop 3.

### 1. Chemical Structures of β~2~-Agonists {#s25}

Almost all *β*~2~-agonist drugs share a similar chemical scaffold as the endogenous ligand epinephrine, which is characterized by an aromatic group as the head (catechol group in epinephrine), an ethanolamine group as the middle moiety, and a tail group with diverse chemical structures ([Fig. 1](#F1){ref-type="fig"}).

![Chemical structures of *β*~2~-agonists. SABAs, LABAs, and ultra-LABAs are indicated by boxes with green, blue, and red colors, respectively.](pr.118.016899f1){#F1}

### 2. Structural Insights into the Pharmacological Properties of β~2~-Agonists {#s26}

#### a. Ligand efficacy {#s27}

Results from structural and biophysical studies of *β*~2~AR have provided a detailed molecular mechanism for how agonists induce receptor activation ([@B510],[@B512]; [@B520]; [@B388]; [@B249]; [@B392]). As for almost all other rhodopsin-like class A GPCRs ([@B183]), the ligand-binding pockets in the *β*~2~AR are located within the helical bundle formed by seven-transmembrane helices (7TMs). Compared with the inactive *β*~2~AR with antagonists and inverse agonists, the binding of agonists at the extracellular region can cause a contraction of the ligand-binding pocket with a slight inward movement of transmembrane helix 5 (TM5), which is linked to large conformational changes at the cytoplasmic surface through a rearrangement of a triad of residues in the middle of the 7TM helical bundle ([@B510]). The conformational changes at the cytoplasmic surface include a rotation and large outward movement of TM6, creating an open cavity to accommodate the C-terminal helix of the G*α*~s~. The outward movement of TM6 at the cytoplasmic surface is a hallmark of GPCR activation.

The aromatic head groups of *β*~2~-agonists together with the ethanolamine group are involved in polar interaction networks with nearby polar residues in the ligand-binding pockets that include serine residues Ser203^5.42^, Ser204^5.43^, and Ser207^5.46^ in TM5; Asn293^6.55^ in TM6; Asp113^3.32^ in TM3; and Asn312^7.39^ in TM7 (Ballesteros--Weinstein numbering system) ([@B294]) ([Fig. 2A](#F2){ref-type="fig"}) ([Supplemental Material 1-PDB IDs 4LDE](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1), [4LDO, and 6MXT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). It has been proposed based on the crystal structures and mutagenesis studies that these polar interactions are critical for inducing a contracted conformational change of the ligand-binding pocket that leads to receptor activation ([@B510]; [@B392]). Different *β*~2~-agonists with distinct head groups may engage in slightly different polar interaction networks with the receptor, resulting in their different receptor activation efficacies ([@B510]; [@B520]; [@B392]). Salmeterol and salbutamol are both partial agonists, and they share the same saligenin head group, which compared with the catechol group has one additional methylene between the *meta*-hydroxyl group and the phenyl ring. In the crystal structures, the two hydroxyl groups in the catechol group of epinephrine or in the saligenin group of salmeterol interact with two serine residues in TM5 through hydrogen bonding ([@B520]; [@B392]). These hydrogen bonds contribute to the inward movement of TM5, which is associated with receptor activation. The additional methylene in the saligenin head group may result in a weaker stabilization of TM5 in the active conformation compared with epinephrine. Results from molecular dynamics (MD) simulation studies also suggested that salmeterol stabilizes a less stable active conformation of *β*~2~AR compared with epinephrine because of the long hydroxymethyl group in the saligenin group of salmeterol ([@B392]). Therefore, the saligenin group in salmeterol and salbutamol accounts for their partial agonism. In contrast, isoproterenol as a classic full agonist shares the same catechol group as epinephrine.

![Binding sites for *β*~2~-agonists revealed by crystal structures. (A) Crystal structures of human *β*~2~AR in complex with epinephrine ([Supplemental Material 1-PDB ID 4LDO](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), BI-167107 ([Supplemental Material 1-PDB ID 4LDE](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), and salmeterol ([Supplemental Material 1-PDB ID 6MXT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). Polar interactions are shown as dashed lines. Residues in *β*~2~AR that interact with each ligand are shown as sticks. (B) Exosite for the binding of the tail group of salmeterol in the crystal structure of human *β*~2~AR with salmeterol ([Supplemental Material 1-PDB ID 6MXT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)).](pr.118.016899f2){#F2}

The synthetic ligand, BI-167107, is a full *β*~2~-agonist and has been used in the structural studies of *β*~2~AR ([@B510],[@B512]). The head group of BI-167107 is distinct from epinephrine or salmeterol, but very similar to the quinoline-2-one group in the ultra-LABA, indacaterol, which is also a full *β*~2~-agonist ([@B584]) ([Fig. 1](#F1){ref-type="fig"}). The head group of BI-167107 contains an amine group at the same position relative to the ethanolamine group as the *meta*-hydroxyl group in the catechol group of epinephrine, allowing it to also form a hydrogen bond with residue Ser203^5.43^ in TM5 ([Fig. 2A](#F2){ref-type="fig"}) ([Supplemental Material 1-PDB ID 4LDE](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). Consistently, formoterol, another full *β*~2~-agonist, also has an amine group in its head group at the same position as the *meta*-hydroxyl group in the catechol group of epinephrine that may form a similar hydrogen bond with Ser203^5.43^. Therefore, it is likely that this hydrogen bond is an important structural determinant for the efficacy of some *β*~2~-agonists.

#### b. Duration of action {#s28}

The mechanism for the duration of in vivo action of *β*~2~-agonist drugs has attracted much research interest since the early development of *β*~2~-agonists. In general, there are many factors that determine the duration of drug action, including the binding and rebinding to the target and the plasma half-life ([@B620]). The first synthetic agonist isoproterenol shares the same pharmacophore as epinephrine, the catechol group, which can be rapidly metabolized by catechol-*O*-methyl transferase. Therefore, initial efforts in the development of long-lasting *β*~2~-agonist compounds were directed at modifying the catechol group. This led to the discovery of salbutamol and terbutaline with noncatechol pharmacophores that are resistant to catechol-*O*-methyl transferase metabolism and demonstrate a prolonged duration of action compared with isoproterenol ([@B627]), even though both drugs are considered as SABAs.

Early pharmacological studies on salmeterol and formoterol as the two classic LABAs provided several possible mechanisms to explain their prolonged action ([@B114]; [@B591]). The diffusion microkinetic model proposed by [@B6] suggested that the high lipophilicity of these two ligands allows them to be able to incorporate into the lipid bilayers in the vicinity of the receptor, and thus the cell membrane acts as a depot and maintains a high local concentration of the drugs. The microkinetic model well explained an interesting pharmacological property of lipophilic LABAs known as the reassertion of relaxation ([@B438]; [@B7]; [@B49]). It has been shown by in vitro studies that *β*~2~AR antagonists can reverse the relaxation of airway tissues by salmeterol and formoterol, but that subsequent washout of all ligands leads to a reappearance of tissue relaxation even when no additional agonist was added. The microkinetic model also explained the concentration-dependent duration of action of formoterol in the washout experiments ([@B591]). However, the duration of action of salmeterol is concentration-independent, and ligand-binding assays suggested a persistent binding of salmeterol to the receptor ([@B445]), which cannot be adequately explained by the microkinetic mechanism. To explain the action of salmeterol, [@B115] proposed another model, the exosite model, suggesting the existence of an exosite in addition to the orthosteric active site in *β*2AR. It is postulated that the exosite accommodates the aryloxyalkyl tail group of salmeterol and acts as an anchoring region to keep the ligand in the vicinity of *β*~2~AR. This model relies on the specific structural characteristic of the aryloxyalkyl tail of salmeterol and provides a favorable interpretation of the unique pharmacological properties of this drug. However, the nature and the location of the exosite have been the subject of debate.

The recently published crystal structure of *β*~2~AR bound to salmeterol clearly revealed the molecular details of the exosite that is located in the extracellular vestibule of *β*~2~AR formed by residues from the extracellular ends of TM6 and TM7 and the extracellular loop (ECL)2 ([@B392]) ([Fig. 2B](#F2){ref-type="fig"}) ([Supplemental Material 1-PDB ID 6MXT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). The ether oxygen atom in the aryloxyalkyl tail of salmeterol forms a hydrogen bond with the main chain amine group of Phe193. It serves as a hinge point where the tail of salmeterol bends to allow the phenyl group at the end of the tail to fit the exosite and form aromatic interactions with the surrounding residues Phe194, Tyr308^7.35^, and His296^6.58^. The position of this ether oxygen has been proven to be important for the binding of salmeterol ([@B276]). Salbutamol, which shares the same saligenin head group as salmeterol, but lacks the long tail, has an almost 1000-fold lower affinity compared with salmeterol with a short-acting property ([@B24]). Therefore, the binding events in the exosite are important for the high-affinity and long-lasting action of salmeterol. Previous mutagenesis studies also suggest that exosite mutations could greatly reduce the affinity of salmeterol, but had little effect on the affinity of salbutamol ([@B25]). Such a binding mode also suggests a bivalent nature of salmeterol. It has been proposed that multivalent ligands that can occupy multiple physically linked sites simultaneously may gain markedly increased affinity and extended receptor residence time through a forced proximity mechanism ([@B620], [@B621]; [@B622]), which most likely applies to salmeterol. The association of one moiety of salmeterol with the receptor, for example, the binding of the tail group in the exosite, forces the other moiety to be in a proximity of its target site to increase the propensity of rebinding, resulting in a prolonged receptor residence time.

Noticeably, one ultra-LABA, vilanterol, is a derivative of salmeterol that contains an additional ether bond and a few other minor modifications ([Fig. 1](#F1){ref-type="fig"}). If vilanterol adopts a similar binding pose as salmeterol, it is possible that this additional ether group may also hydrogen bond with the receptor, providing more structural restrictions to the flexible aryloxyalkyl tail to enhance the binding of this tail in the exosite. This may explain the longer duration of action of vilanterol compared with salmeterol ([@B571]). Other ultra-LABAs such as olodaterol and indacaterol do not contain long tail groups, but share a high chemical similarity with BI-167107, the *β*~2~-agonist used in several structural studies of *β*~2~AR. BI-167107 is not a drug, but it has been shown to exhibit an extremely slow dissociation rate ([@B510]). Compared with the catechol group in epinephrine, the hydroxylquinoline ring head group of BI-167107 forms a more extensive aromatic interaction network with surrounding aromatic residues as well as additional hydrogen bonds between the ether oxygen of the quinolone ring and side chains of residues Asn293^6.55^ and Tyr308^7.35^. In addition, the methylbenzene ring tail group of BI-167107 forms hydrophobic and aromatic interactions with residues His93^2.64^, W109^3.28^, and Ile309^7.36^. Those additional interactions contribute to the high affinity and slow dissociation rate of BI-167107. A similar structural mechanism may also explain the long-lasting action of olodaterol and indacaterol. These two compounds contain large aromatic head groups such as the quinoline-2-one group in indacaterol and additional aromatic tail groups that can engage in more extensive interactions with the receptor compared with epinephrine, resulting in a stronger binding to the receptor.

#### c. Receptor--subtype selectivity {#s29}

As discussed before, a high selectivity of *β*~2~-agonist over *β*~1~AR may help to reduce its cardiac toxicity. Salmeterol is a highly selective *β*~2~-agonist developed in 1980s ([@B26]) with a ∼3000-fold selectivity for *β*~2~AR over *β*~1~AR ([@B24]). The exosite revealed by the crystal structure that accommodates the long tail group of salmeterol well explains such high selectivity. Two aromatic residues that directly interact with salmeterol in the exosite, F194 and H296^6.58^ ([Fig. 2B](#F2){ref-type="fig"}) ([Supplemental Material 1-PDB ID 6MXT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), are replaced by two nonaromatic residues N313 and V202 in the *β*~1~AR, which would significantly compromise salmeterol binding to *β*~1~AR. The sampling of the nonconserved region, the exosite, by salmeterol results in its high selectivity. Also consistent with the proposed mechanism is the decreased selectivity of salbutamol (20-fold for *β*~2~AR), which lacks the tail group required for exosite interaction.

*β*~1~AR and *β*~2~AR share a very high sequence similarity ([@B392]). Specifically, their orthosteric ligand-binding pockets are structurally very similar to each other, which is expected, as both receptors recognize the same endogenous ligands. Therefore, ligands that primarily occupy the conserved orthosteric binding pockets usually do not have high receptor--subtype selectivity. The same problem is well studied for another GPCR family, the muscarinic acetylcholine receptor family with five members, M1~--~5 receptors (M1--5R), which will be discussed in details in the next section. Because they all recognize the same endogenous ligand, they share a highly similar orthosteric site. Traditional muscarinic antagonists targeting the orthosteric sites are generally associated with low selectivity and severe side effects ([@B332]). However, there are well-characterized allosteric ligand-binding sites in these receptors that are structurally distinct from the conserved orthosteric sites. These allosteric sites are divergent among all five muscarinic acetylcholine receptors, which offer great opportunities for designing allosteric modulators for each muscarinic acetylcholine receptor that can achieve high receptor--subtype selectivity ([@B144]). Interestingly, the exosite in *β*~2~AR is reminiscent of the allosteric site in M2R revealed by crystal structures ([@B392]). As an old drug that was developed more than three decades ago, salmeterol may belong to a new type of GPCR-targeting drug that started emerging recently, the bitopic drugs, which can occupy both the orthosteric and allosteric sites ([@B297]). These drugs may be designed rationally with sufficient structural information to gain desired pharmacological properties.

#### d. Biased signaling {#s30}

The first structural insights into the biased signaling of *β*~2~AR came from NMR studies using a ^19^F-labeled receptor in the presence of a number of ligands, including two *β*-arrestin--biased ligands, carvedilol and isoetharine ([@B369]). The results suggested that the tail groups of these two ligands might be the structural determinants for their biased signaling properties, which directly interact with the extracellular part of TM7. In the experiments, carvedilol and isoetharine affected the conformational equilibrium of TM7 in different ways compared with nonbiased *β*~2~AR ligands. The conformation of TM7 is believed to play an important role in the functional selectivity of *β*~2~AR.

However, data from the structural and site-directed mutagenesis studies, investigating salmeterol action, suggested that the interactions between the ligand head group and the receptor affect the biased signaling properties of salmeterol ([@B392]). In the structure of *β*~2~AR bound to epinephrine ([Supplemental Material 1-PDB ID 4LDO](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), the two hydroxyl groups in the catechol head group of epinephrine are involved in a polar interaction network with residues Ser204^5.43^ and Asn293^6.55^. Mutations of these two residues could significantly compromise *β*-arrestin recruitment by the full agonist isoproterenol, but had more moderate effects on the G~s~ activation. In the structure of *β*~2~AR bound to salmeterol ([Supplemental Material 1-PDB ID 6MXT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), Ser204^5.43^ and Asn293^6.55^ are not involved in the direct polar interactions with the saligenin group of salmeterol, and mutations of these two residues also had moderate effects on the G~s~ activation. It was proposed that the lack of direct interaction between the head group of salmeterol and Asn293^6.55^ might account for the weak ability of salmeterol in recruiting *β*-arrestins. This mechanism may also explain the biased signaling property of salbutamol that shares the same saligenin head group with salmeterol ([@B616]).

III. Muscarinic Acetylcholine Receptors and Muscarinic Antagonists {#s31}
==================================================================

A. Pathophysiological Roles and Signaling of Muscarinic Receptors in Asthma {#s32}
---------------------------------------------------------------------------

Muscarinic and nicotinic cholinergic receptors mediate metabotropic and ionotropic effects of acetylcholine on the central and peripheral nervous systems ([@B90]). Muscarinic acetylcholine receptors (MRs, or mAChRs), which are more sensitive to muscarine than to nicotine, are a group of class A GPCRs comprising five distinct subtypes, named as muscarinic M1, M2, M3, M4, and M5 receptors (M1R--M5R) ([@B230]; [@B231]; [@B410]; [@B150]; [@B288]; [@B90]; [@B91]; [@B272]). M1R, M3R, and M5R are coupled to the G~q/11~ family of G proteins, whereas M2R and M4R are coupled to the G~i/o~ family of G proteins.

MRs are expressed by structural cells in the airways, predominantly ASM, airway epithelium, and airway fibroblasts ([@B207]; [@B502]; [@B506]; [@B632]; [@B318]). Acetylcholine binds to airway MRs to trigger smooth muscle contraction and mucus secretion. M2R and M3R have been shown to play major roles in airway physiology, and in diseases such as asthma and COPD ([@B215]; [@B474]; [@B283]; [@B505]; [@B69]; [@B319]; [@B176]).

M2R are expressed on ASM and on parasympathetic neurons. Although M2R is the major type of MR expressed on ASM ([@B524]; [@B221]), it has a very limited role in ASM contraction. M2R can activate the G*α*~i~ subunit, which can then bind to and inhibit adenylyl cyclases activated by G*α*~s~. Thus, M2R activation constrains the signaling and bronchorelaxant effects of *β*~2~AR by antagonizing *β*~2~AR/G~s~ activation of adenylyl cyclases ([@B336]; [@B177]; [@B546]). However, M2R expressed presynaptically on the parasympathetic nerve endings, when activated, exerts negative feedback on neuronal acetylcholine release, thereby limiting bronchoconstriction. The dysfunction of the presynaptic M2R has been proposed as a pathophysiological mechanism of AHR in asthma ([@B186]).

M3R are the dominant receptor subtype for bronchial smooth muscle contraction, and are found in airway smooth muscle and submucosal glands ([@B386]; [@B220]; [@B177]; [@B385]; [@B32]; [@B583]; [@B207]; [@B69]). M3R can mediate ASM contraction through both calcium-dependent and calcium-independent mechanisms ([@B237]; [@B207]; [@B63]). The calcium-dependent mechanism is centered on Gq-mediated phospholipase C activation. Stimulation of M3R on ASM by acetylcholine initiates a conformational change in the receptor that promotes its association and activation of the heterotrimeric G protein G~q~. The activated *α* subunit of Gq in turn activates membrane-bound phospholipase C, which hydrolyzes phosphatidylinositol 4,5-bisphosphate into 1,2-diacylglycerol and inositol 1,4,5-trisphosphate. Inositol 1,4,5-trisphosphate diffuses into the cytosol and binds its receptor, the inositol triphosphate receptor on the sarcoplasmic reticulum, thereby augmenting the release of Ca^2+^. The rise in intracellular free Ca^2+^ next enhances conductivity of neighboring ryanodine receptors, and together they generate a transient Ca^2+^ wave ([@B208]; [@B106]; [@B525]). Increased Ca^2+^ induces the formation of Ca^2+^/calmodulin complexes capable of activating myosin light chain kinase. The subsequent phosphorylation of myosin light chain allows the actin--myosin cross-bridge cycle to operate. In parallel, both Ca^2+^ and 1,2-diacylglycerol recruit protein kinase C (PKC) to the membrane. The activated PKC phosphorylates an inhibitory regulator (named CPI-17) of the downstream myosin-light chain phosphatase (MLCP), promoting the affinity between the CPI-17 and MLCP. MLCP inhibition enhances Ca^2+^ sensitivity of the system. In contrast, the mechanism by which the M3R mediates calcium-independent ASM contraction is referred to calcium sensitization ([@B52]) via activation of the small GTPase RhoA that in turn activates Rho-kinase. RhoA and Rho-kinase augment agonist-induced contraction primarily by inactivating MLCP. MLCP is inhibited by the direct phosphorylation of its regulatory myosin-binding subunit by Rho-kinase and by binding to CPI-17, which is targeted for phosphorylation by both Rho-kinase and PKC, resulting in higher levels of phosphorylated myosin and smooth muscle contraction ([@B207]).

B. Currently Used Muscarinic Antagonist Drugs and Their Pharmacological Properties {#s33}
----------------------------------------------------------------------------------

Numerous anticholinergic compounds derived from plant alkaloids (*Datura stramonium* and *Atropa belladonna*) were used historically, long before *β*-agonists, for the treatment of asthma symptoms ([@B409]; [@B277]). Atropine, along with hyoscyamine and scopolamine, were some of the anticholinergic compounds first isolated from plant alkaloids in 1833. Its bronchodilator properties were first used for asthma from the late 18th century. Atropine and other anticholinergic agents exert their bronchodilator effects through the blockade of MRs in the airways. As a tertiary ammonium derivative, atropine is a nonselective antagonist with similar affinity for all of the MR subtypes ([@B421]; [@B69]). The half-life of atropine for M3R residence is 3.5 hours. Although extensively used in the past, atropine is rarely used at the present time because it is well absorbed into the systemic circulation and penetrates the blood--brain barrier, leading to multiple systemic side effects, including tachycardia ([@B148]; [@B572]; [@B94]).

In the 1970s, new anticholinergic medications were developed, given the need to develop alternatives to *β*~2~-agonist therapies. The newer anticholinergic agents are water-soluble, quaternary ammonium compounds that are poorly absorbed, and, when administered by inhalation, cause fewer systemic side effects ([@B213]). Among them, ipratropium bromide and oxitropium bromide are short-acting muscarinic antagonist (SAMA) drugs that have been used in the treatment of respiratory diseases. Like atropine, they are also nonselective anticholinergics, blocking both the prejunctional M2R and postjunctional M3R. The SAMA agent ipratropium bromide is a synthetic quaternary ammonium compound that is chemically related to atropine. Its half-life for M3R residence is 3.2 hours. Oxitropium bromide is based on the scopolamine, and its half-life is slightly longer.

Several long-acting muscarinic antagonists (LAMAs) are under investigation or are available for the treatment of obstructive airway diseases. Tiotropium bromide is also a quaternary ammonium derivative compound with two thiophene rings, displaying a much higher affinity (6- to 20-fold) for MRs compared with ipratropium bromide ([@B221]). It has a similar affinity for the M2R and M3R; however, unlike ipratropium, tiotropium is functionally selective for the M3R because of its longer pharmacological half-life for the M3R (35 hours vs. 3.6 hours for M2R) ([@B145]). Initially indicated for the treatment of COPD ([@B85]), tiotropium bromide (Respimat) received Food and Drug Administration approval in 2017 for the use in children with asthma aged 6 years or over ([@B206]). In fact, tiotropium is the only LAMA that has been studied extensively in asthma, and is the first agent in the class to be indicated as add-on therapy for patients with asthma who are currently treated with maintenance ICS only or ICS and LABA therapy.

In addition to tiotropium, three other LAMAs (aclidinium, umeclidinium, and glycopyrrolate) used in the treatment of COPD have the potential to be developed as therapies for asthma. Two of these LAMAs (umeclidinium and glycopyrrolate) are currently being investigated in clinical trials for asthma ([@B197]; [@B354]; [@B75]; [@B178]). Aclidinium is similar to tiotropium with a quaternary ammonium group and two thiophene rings, and, although it has a similar affinity for M2R and M3R, it is also functionally selective for M3R based on its extended half-life of 29 hours ([@B193]; [@B421]). Aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites (plasma half-life = 2.4 minutes), thus minimizing systemic side effects. Glycopyrrolate is a M3R selective antagonist with 3--5 times higher affinity for the M3R compared with the M2R ([@B194]). Its half-life was reported to be 3.7 hours ([@B222]; [@B421]). The newest LAMA is umeclidinium bromide, which also has a greater affinity M3R based on its slower dissociation from M3R compared with the M2R (82 vs. 9 minutes) ([@B534]).

LAMAs are considered to be safe drugs at recommended dosages. However, because MRs are expressed not only in the lungs, but also in the heart and the digestive and urinary tracts, the blockade of different MR subtypes in these organs by LAMA treatment can cause diverse, unwanted physiologic effects. For example, these agents can initially block prejunctional M2R on cholinergic airway nerves that normally reduce the release of the bronchoconstricting neurotransmitter acetylcholine, thus resulting in cough and paradoxical bronchoconstriction ([@B389]; [@B355]; [@B569]; [@B94]). Side effects including cardiovascular morbidity and mortality of inhaled LAMA agents in asthma need to be further studied and defined.

The combination therapy of ICS and bronchodilator has been a mainstay for asthma management for nearly 50 years. However, there are limited options for those who continue to have asthma exacerbations while taking combination ICS/LABA treatment. Thus, the addition of anticholinergics as an add-on therapy to the current regimes may provide alternative treatments to those who are unresponsive on their current treatments or for those who are refractory to *β*~2~-agonists. There are still safety concerns regarding the continued use of *β*~2~-agonists, especially for those with the single-nucleotide polymorphisms in the *β*~2~-adrenergic receptor gene ADRB2, or for children where reduced bone density and growth are a concern ([@B518]; [@B465]; [@B472]). To date, the benefits seen with tiotropium as an add-on therapy in the subgroup of asthmatics with poorly controlled symptomatic asthma also suggest that a broad range of patients with asthma may benefit from anticholinergic therapy regardless of their respective baseline characteristics. Continued research into the mechanism of acetylcholine signaling in asthma and the results of ongoing clinical studies will promote the broader use of anticholinergics as add-on or stand-alone therapies for the management of asthma symptoms.

C. Structural Insights into Drug Action {#s34}
---------------------------------------

### 1. Chemical Structures of Clinically Used Muscarinic Antagonists {#s35}

Almost all of muscarinic antagonist drugs share a similar chemical scaffold as atropine, characterized by an ester between an aromatic ring derivative and a modified tropane or quinuclidine moiety containing a positively charged quaternary ammonium group ([Fig. 3](#F3){ref-type="fig"}).

![Chemical structures of currently used muscarinic antagonist drugs. (A) Ipratropium and oxitropium as SAMAs. (B) Tiotropium, aclidinium, umeclidinium, and glycopyrrolate as LAMAs.](pr.118.016899f3){#F3}

### 2. Structural Insights into the Pharmacological Properties of Clinically Used Muscarinic Antagonists {#s36}

Since the first high-resolution structure of a MR was solved by X-ray crystallography in 2012 ([@B223]), 15 structures have been deposited in PDB for M1R, M3R, and M4R at inactive antagonist-bound states ([@B331]; [@B602]; [@B597]; [@B367]), and for M2R at both inactive and active states ([Table 3](#T3){ref-type="table"}) ([@B223]; [@B333]; [@B588]). The overall transmembrane structure is similar to those of rhodopsin ([@B469]) and *β*~2~AR ([@B528]), which has a conserved disulfide bond between Cys^3.25^ at the N terminus of TM3 and another Cys residue in the ECL2. MR also has an additional disulfide bond between two Cys residues in the ECL3. The orthosteric binding pocket is formed by amino acids that are identical in all five MR subtypes. A layer of tyrosine residues forms an aromatic cap restricting dissociation of the bound ligand. An allosteric ligand-binding site has been identified at the entrance to the binding pocket near this aromatic cap.

###### 

Structures of human M1, M2, and M4 receptors, and rat M3 receptor

  Receptor      PDB ID   Ligand               Efficacy                  Fusion Partner                      Resolution (Å)   References
  ------------- -------- -------------------- ------------------------- ----------------------------------- ---------------- ------------
  M1R           5CXV     Tiotropium           Inverse agonist           T4 lysozyme (T4L) in ICL3           2.70             [@B597]
  M2R           3UON     QNB                  Inverse agonist           T4L in ICL3                         3.00             [@B223]
  M2R           4MQS     Iperoxo              Full agonist              None                                3.50             [@B333]
  M2R           4MQT     Iperoxo, LY2119620   Full agonist, PAM         None                                3.70             [@B333]
  M2R           5ZK8     NMS                  Inverse agonist           Cytochrome b562RIL (BRIL) in ICL3   3.00             [@B588]
  M2R (S110R)   5ZKC     NMS                  Inverse agonist           BRIL in ICL3                        2.30             [@B588]
  M2R (S110R)   5ZKB     AF-DX 384            Antagonist                BRIL in ICL3                        2.95             [@B588]
  M2R (S110R)   5ZK3     QNB                  Inverse agonist           BRIL in ICL3                        2.60             [@B588]
  M2R (S110R)   5YC8     NMS, Hg              Inverse agonist, cation   BRIL in ICL3                        2.50             [@B588]
  M3R           4DAJ     Tiotropium           Inverse agonist           T4L in ICL3                         3.40             [@B331]
  M3R           4U14     Tiotropium           Inverse agonist           Disulfide stabilized T4L in ICL3    3.57             [@B602]
  M3R           4U15     Tiotropium           Inverse agonist           Minimal T4L (mT4L) in ICL3          2.80             [@B602]
  M3R           4U16     NMS                  Inverse agonist           mT4L in ICL3                        3.70             [@B602]
  M3R           5ZHP     Compound 6o (BS46)   Antagonist                mT4L in ICL3                        3.10             [@B367]
  M4R           5DSG     Tiotropium           Inverse agonist           mT4L in ICL3                        2.60             [@B597]

#### a. Ligand efficacy {#s37}

Over the past decade, the M1R--M4R were crystallized, and their structures were solved with antagonists such as tiotropium, 3-quinuclidinyl benzilate (QNB), and N-methyl scopolamine (NMS). These ligands have similar chemical structures and bind in similar positions in the orthosteric site ([Fig. 4A](#F4){ref-type="fig"}) ([Supplemental Material 1-PDB IDs 3UON](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1), [4DAJ](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1), [5CXV, and 5DSG](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), which is also the binding site for the endogenous agonist acetylcholine. This orthosteric site is buried within the 7TM core. Strikingly, amino acid sidechains on TM3, 4, 5, 6, and 7 that surround these ligands are fully conserved among all five MR subtypes and are located in similar positions in the orthosteric site across the M1R--M4R structures. The natural agonist acetylcholine is much smaller than these antagonists. Bulky antagonists capable of blocking activation-related contraction of the pocket would be very efficient in locking MRs in an inactive conformation.

![Binding sites in MR crystal structures. (A) Orthosteric sites for tiotropium in the crystal structures of tiotropium-bound M1R (top left, [Supplemental Material 1-PDB ID 5CXV](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), M3R (bottom right, [Supplemental Material 1-PDB ID 4DAJ](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), and M4R (top right, [Supplemental Material 1-PDB ID 5DSG](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), and the orthosteric site for QNB in the crystal structure of M2R (bottom left, [Supplemental Material 1-PDB ID 3UON](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). Polar interactions are shown as dashed lines. (B) Crystal structure of active M2R with the orthosteric agonist iperoxo only (left, [Supplemental Material 1-PDB ID 4MQS](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1), allosteric site empty) and crystal structure of active M2R with iperoxo and a PAM named LY2119620 (right, [Supplemental Material 1-PDB ID 4MQT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). Full agonist iperoxo is in the orthosteric site of both structures.](pr.118.016899f4){#F4}

M1R, M3R, and M4R have been crystallized in complex with tiotropium, the potent, nonsubtype-selective antagonist ([Fig. 4A](#F4){ref-type="fig"}). Like atropine and other conventional muscarinic antagonists, tiotropium can be considered an inverse agonist because it is able to inhibit both basal and ligand-independent MR signaling ([@B87]). The ligand is almost completely occluded from solvent by a lid comprised of three conserved tyrosines, Tyr^3.33^, Tyr^6.51^, and Tyr^7.39^. Besides the extensive hydrophobic contacts with the receptor, the bound tiotropium also forms a pair of H-bonds between the ligand hydroxyl/ketone and the conserved Asn^6.52^, as well as charge--charge interactions between the ligand cationic amine and the conserved Asp^3.32^. The charge--charge interactions involving Asp^3.32^ are seen in all biogenic amine receptor structures solved to date and have been shown to make a major energetic contribution to binding ([@B334]). The hydrogen-bonding interactions involving Asn^6.52^ seem to be a unique feature for the MR. This feature was suggested to be an important factor in slowing down ligand dissociation ([@B595]). These interactions also explain the extremely high affinity of tiotropium for M3R (Ki = 0.010 nM) and all other MR subtypes (e.g., Ki = 0.020 nM for M2R) ([@B145]; [@B86]; [@B69]).

As noted above, the orthosteric binding pocket is highly conserved among all MR subtypes. Nevertheless, MR structures display a unique feature---a rather large solvent-accessible vestibule facing the extracellular space (termed extracellular vestibule) that is separated from the orthosteric site by the tyrosine lid. Rearrangement of the tyrosine lid and possibly the ECLs is required to enable tiotropium to exit from the orthosteric binding pocket. In comparison with the highly conserved orthosteric site, the extracellular vestibule is least conserved across the muscarinic subtypes, showing multiple sequence differences. In the MD simulation studies of M2R and M3Rs with tiotropium, the ECLs, especially the ECL2, appeared to be more flexible in the M2R as compared with the M3R ([@B331]), suggesting a higher energy barrier to be overcome for tiotropium to exit from the M3R. The observations from MD simulations are consistent with mutagenesis data and data from dissociation experiments of tiotropium, which suggested that the more flexible loop region in the M2R in combination with the lack of residue Lys^7.32^ causes the kinetic selectivity of the M3R over the M2R ([@B595]). These structural observations explain tiotropium's clinically important kinetic selectivity, long duration of action, and minimal non-M3R--mediated side effects.

#### b. Receptor subtype selectivity in the orthosteric site {#s38}

Although residues lining the orthosteric site in the MR family are absolutely conserved, this high degree of sequence conservation does not preclude the existence of differences in the three-dimensional architecture of the orthosteric site between the different receptor subtypes ([Fig. 4A](#F4){ref-type="fig"}). In the M4R structure ([Supplemental Material 1-PDB ID 5DSG](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)), Asn^3.32^ has its rotamer point away from tiotropium and forms a network of H-bond interactions with neighboring residues such as Tyr^7.39^ and Tyr^7.43^, which is distinct from the M1R, M2R, and M3R orthosteric sites. The tiotropium-bound M1R, M3R, and M4R and QNB-bound M2R structures also show considerable differences in the conformations of residues Asn^3.32^, Tyr^7.39^, and Tyr^7.43^~.~ Such differences contribute to the marked difference in the potency for pirenzepine, which serves as a canonical orthosteric antagonist of MRs, with a rank order potency of M1R \> M4R \> M3R \> M2R ([@B91]; [@B597]). This suggests that ligand selectivity can be achieved through subtle differences in the receptor conformational dynamics.

One such structural difference near the orthosteric site in M2R and M3R results from the replacement of Phe181 in the ECL2 of the M2R with Leu225 in M3R, which interacts with one aromatic ring of the bound tiotropium or QNB. This creates a pocket in the M3R not found in the M2R. This single amino acid difference was exploited in the development of subtype-selective ligands. Using molecular docking and structure-based design strategy, [@B367] discovered a M3R-selective antagonist that showed up to 100-fold selectivity over the M2R in in vitro assays and over 1000-fold selectivity when tested in vivo.

Recently, a M2R structure with a mutation S110R was solved in complex with a M2R/M4R-selective antagonist AF-DX 384 ([@B588]) ([Supplemental Material 1-PDB ID 5ZKB](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). This ligand has a higher affinity for M2R/M4R than for M1R/M3R. In other M2R structures with QNB, the orthosteric ligand is almost completely occluded from the solvent with the tyrosine lid located directly above the ligand ([@B223]). By contrast, in the AF-DX 384-bound S110R M2R structure, the tyrosine lid opens up and the orthosteric site becomes more accessible from the extracellular space, thus allowing the two propyl groups of AF-DX 384 to extend from the orthosteric pocket toward the extracellular surface. Because the residues forming contacts with AF-DX 384 are completely conserved among MRs, the residues responsible for subtype selectivity cannot be identified based on the crystal structure alone. In MD simulations of the wild-type M2R and M3R with AF-DX 384, ligand--receptor contacts were found to be tighter with a few residues in TM2, TM3, and TM6 in the M2R. This observation suggested that the subtype selectivity of AF-DX 384 may be a consequence of not only the static interaction seen in the crystal structure, but also the protein dynamics---tightening of the ligand--receptor contacts in the M2R compared with the M3R.

#### c. The structural basis for the action of allosteric modulators as potential novel asthma drugs {#s39}

Before crystal structures were solved for MRs, evidence from functional assays proved the existence of allosteric modulators of these receptors ([@B376]; [@B111]). Some modulators such as gallamine and alcuronium were reported to interact with MRs, but not to compete with orthosteric ligands such as acetylcholine ([@B582]; [@B503]). These modulators limit or enhance the binding of orthosteric ligands and also slow their dissociation, resulting in slowed binding kinetics. Extensive studies of these modulators strongly suggested a common allosteric site on all five MRs ([@B212]). Mutagenesis experiments further implicated contributions from ECL2, ECL3, and the top of TM7 to this common allosteric site ([@B359]; [@B327]; [@B72]; [@B279]). Multiple novel MR ligands with high subtype selectivity have been predicted to target this allosteric site ([@B144]; [@B310]) or occupy both allosteric and orthosteric sites simultaneously (bitopic ligands) ([@B58]; [@B347]).

This predicted common allosteric site was confirmed and clearly illustrated in the solved crystal structures of M1R--M4R ([Table 3](#T3){ref-type="table"}). This allosteric site, termed the extracellular vestibule, is lined by residues that have been previously implicated in the binding of allosteric modulators. It is located directly above (extracellular to) the orthosteric binding site, also consistent with the observation that many muscarinic allosteric modulators can slow dissociation of orthosteric ligands ([@B330]). In comparison with the highly conserved orthosteric site, the extracellular vestibule is less conserved in sequence across the muscarinic subtypes, for example, M2R and M3R can differ by up to 11 substitutions among the 24 residues around this allosteric site ([@B325]). The divergence in amino-acid composition leads to distinct differences in both the shape and charge distribution of the allosteric site, and likely the dynamics of the ECL regions. These observations from MR structures can explain why some of the best-studied MR allosteric modulators such as gallamine are cationic compounds ([@B597]). A segment of acidic amino acids, EDGE, in the ECL2 of the M2R, has been found important for the higher binding potency of gallamine for the M2R compared with the other four MR ([@B200]).

In comparison with the large extracellular vestibule in the inactivate MR structures, this outer cavity in the M2R undergoes a pronounced contraction upon agonist/nanobody-triggered activation, primarily due to the inward movement of the extracellular portion of TM6 ([@B333]) ([Fig. 4B](#F4){ref-type="fig"}) ([Supplemental Material 1-PDB ID 4MQT](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). Importantly, one of the agonist-bound active M2R structures was solved in complex with LY2119620, a positive allosteric modulator (PAM), providing the first structural view of how a drug-like allosteric ligand binds to a GPCR. In this complex structure, the allosteric modulator is located directly above the orthosteric agonist. The contraction in the extracellular vestibule results in a narrower allosteric site and a smaller orthosteric site. The much smaller size of the orthosteric site is reflected by the lower molecular weight of muscarinic agonists compared with antagonists and inverse agonists ([@B330],[@B332]). The agonist-stabilized contraction of the extracellular vestibule enables the PAM to engage in extensive interactions with this outer receptor cavity, which include aromatic stacking, H-bonding, and charge--charge interactions. In particular, the aromatic rings of the PAM are situated directly between Tyr177 in ECL2 and Trp422^7.35^, forming a three-layered aromatic stack. Interestingly, the two active structures of the M2R are highly similar irrespective of whether the PAM is bound, suggesting that the allosteric site conformation is largely preformed after the binding of the orthosteric agonist ([Fig. 4B](#F4){ref-type="fig"}) ([@B333]). These findings support the concept that muscarinic PAMs enhance the receptor affinity of orthosteric agonists by stabilizing the active conformation of the receptor and slowing agonist dissociation from the orthosteric site.

These crystal structures of human and rat MRs solved at both inactive and active states, together with MD simulation and mutagenesis studies, provided a solid basis for the development of subtype-selective therapeutics. Specifically, the extracellular vestibule represents an attractive target for the development of subtype-selective allosteric agents for MRs. Recently, a structure-based docking campaign was prosecuted against the allosteric site observed in the antagonist-bound inactive structure of M2R, which led to the discovery of a new PAM ([@B325]). It has been shown to enhance the binding of NMS and the drug scopolamine itself. Furthermore, this PAM slowed the dissociation rate of NMS from the M2R by 50-fold, but did not demonstrate similar effects on other MRs ([@B325]). This study supports the feasibility of discovering PAMs that confer subtype selectivity to nonselective orthosteric drugs of MR, which are expected to reduce the off-target effects of nonselective orthosteric drugs in asthma.

IV. Cysteinyl Leukotriene Receptors and Leukotriene Antagonists {#s40}
===============================================================

A. Pathophysiological Roles and Signaling of Cysteinyl Leukotriene Receptors in Asthma {#s41}
--------------------------------------------------------------------------------------

### 1. Cysteinyl Leukotriene Synthesis {#s42}

CysLTs are a class of bioactive fatty acids whose formation and signaling are associated with airway inflammation. These endogenous bioactive fatty acids are derived from the *ω*-6 eicosanoid, arachidonic acid (AA). AA is esterified in phospholipids at the sn2 position, and under conditions of stress it is released by phospholipase A~2~ and metabolized into bioactive fatty acids primarily through cyclooxygenase to form PGs or lipoxygenase pathways ([@B188]; [@B136]). Leukotrienes are generated by 5-LOX in leukocytes. Specifically, 5-LOX together with 5-LOX--activating protein transforms AA into 5-hydroperoxyeicosatetraenoic acid. The peroxide of 5-hydroperoxyeicosatetraenoic acid spontaneously reduces to form 5-hydroxyeicosatetraenoic acid (5-HETE). 5-HETE is also a substrate for 5-LOX in which the end product is the epoxide ring containing leukotriene A~4~ (LTA~4~). LTA~4~ can be either rapidly hydrolyzed by LTA~4~ hydrolase to form LTB~4~ or conjugated with glutathione, a reaction that is catalyzed by LTC~4~ synthase to generate LTC~4~ as the first CysLT in this pathway. Once transported out of cells, LTC~4~ can then be metabolized by extracellular enzymes to form LTD~4~ and LTE~4~. Some studies also suggested that certain cells expressing LTC~4~ synthase can catalyze the conversion of extracellular LTA~4~ to LTC~4~, providing another source of CysLTs ([@B381]). LTC~4~, LTD~4~, and LTE~4~ are the major bioactive members of the CysLT family, all of which are lipid and peptide hybrid molecules with a cysteine amino acid attached to the C6 of the fatty acid chain ([Fig. 5](#F5){ref-type="fig"}). In the airways, CysLTs are mainly generated and released from innate immune cells, including eosinophils, basophils, and mast cells ([@B153]).

![Chemical structures of CysLTs and LTRAs.](pr.118.016899f5){#F5}

### 2. Pathophysiological Roles and Signaling of Cysteinyl Leukotriene Receptors {#s43}

A term, slow-reacting substance of anaphylaxis, was introduced in the early 20th century to describe some mediators other than histamine to induce anaphylaxis and result in prolonged contraction of bronchial smooth muscle after allergen challenge ([@B18]). Such mediators have been shown to induce symptoms of asthma. Studies from several groups using various biophysical and physiologic approaches later demonstrated that slow-reacting substance of anaphylaxis was actually a mixture of CysLTs ([@B21]; [@B419], [@B420]; [@B361]; [@B536]). Further studies in the next decade revealed pivotal roles of CysLTs, especially LTC~4~ and LTD~4~, in the pathogenesis of asthma. A major breakthrough during that period was the identification and characterization of two GPCRs, CysLT receptor (CysLTR)~1~ and CysLTR~2~, as the main targets for LTC~4~ and LTD~4~ ([@B342]; [@B379]; [@B592]).

CysLTR~1~ and CysLTR~2~ have different tissue expression profiles and different preferences for CysLTs ([@B343]; [@B370]; [@B668]). CysLTR~2~ has been confirmed to be highly expressed in the heart and coronary smooth muscle cells, where little CysLTR~1~ was detected. Both receptors are expressed in innate and adaptive immune cells and lung smooth muscle cells, although they play different roles in asthma and other inflammatory conditions. CysLTR~1~ prefers LTC~4~ over LTD~4~, whereas LTC~4~ and LTD~4~ are equally potent agonists of CysLTR~2~. Both receptors exhibit low affinities for LTE~4~. Multiple studies suggested the existence of another receptor for LTE~4~, the molecular identity of which is still in debate ([@B343]). Both CysLTR~1~ and CysLTR~2~ mainly signal through the G~q/11~ family to evoke cellular Ca^2+^ responses and cause bronchoconstriction ([@B205]; [@B575]). CysLTR~1~ has also been shown to induce signaling events that are sensitive to pertussis toxin in some cells, including ASM cells, indicating the involvement of the G~i/o~ family ([@B495]; [@B258]; [@B405]; [@B286]; [@B514]). These studies suggested that G~i/o~-mediated signaling leads to the activation of MAPK.

CysLTs act on the CysLTRs to exert their roles in asthma through multiple mechanisms. During the 1980s, a number of laboratories reported the potent bronchoconstriction action of LTC~4~ and LTD~4~ on isolated human bronchi or in humans ([@B128], [@B127]; [@B255]; [@B641]; [@B54]). Several studies showed that CysLTs are hundreds or even thousands of times more potent than histamine in inducing bronchial contraction ([@B641],[@B642]; [@B152]). Compared with LTC~4~ and LTD~4~, LTE~4~ is a weaker bronchoconstrictor, as suggested by several studies, although asthmatic patients showed an increased sensitivity to LTE~4~ ([@B133]; [@B17]). The inherent tone of human airway tissues is believed to be maintained by the balance between contractile and vasodilating mediators ([@B159]; [@B637]). Overproduction of CysLTs can enhance the contractile tone by inducing smooth muscle hyperplasia in asthma ([@B264]). The involvement of CysLTR~1~ in the bronchoconstrictor effects of CysLTs is well validated by clinical trials with LTRAs that specifically target CysLTR~1~ ([@B398]). Recently, [@B670] and [@B552], [@B553] demonstrated that CysLTR~2~ also plays important roles in CysLT-induced bronchoconstriction, suggesting a potential therapeutic benefit of blocking both CysLTR~1~ and CysLTR~2~ in reducing bronchoconstriction.

CysLTs also play important roles in the inflammatory process involved in the pathogenesis of asthma. [@B344] reported the effects of LTE~4~ in the recruitment of eosinophils and neutrophils in the airway mucosa. Other studies also demonstrated the positive effects of CysLTs, in particular LTD~4~, on the migration of eosinophils into the airways and proposed that CysLTs contributed to the airway eosinophilia ([@B181]; [@B574]; [@B243]). This is partly due to the abilities of CysLTs to induce the expression of adhesion molecules on leukocytes ([@B301]; [@B481]; [@B184]; [@B432]). [@B353] showed that CysLTs could stimulate eosinophil survival, which was reversed by a LTRA. Cumulatively, these studies suggested the chemotactic effects of CysLTs for eosinophils in asthma. CysLTs have also been shown to simulate the generation of potent inflammatory mediators by eosinophils such as eosinophilic cationic protein, eosinophilic protein X, neurotoxin, and superoxide radicals ([@B489]). Treatment with LTD~4~ antagonists, which are CysLTR~1~ selective, was shown to reduce airway eosinophil influx and eosinophilia in several species ([@B344]; [@B576]; [@B613]; [@B615]). In vitro studies also showed that antagonists of CysLTRs could downregulate type 2 cytokines and thus reduce T~H~2-mediated inflammation ([@B607]; [@B28]; [@B404]). In addition, several type 2 cytokines, such as IL-4 and IL-5, could enhance the synthesis of CysLTs by modulating the location and activities of 5-LOX and LTC~4~ synthase ([@B122]; [@B458]). IL-4, IL-5, and IL-13 have also been shown to upregulate the expression of CysLTR~1~ in several leukocytes and smooth muscle cells, providing a positive feedback mechanism to augment the inflammatory responses induced by CysLTs ([@B600]; [@B404]; [@B163]).

The potent bronchoconstriction and proinflammatory effects of CysLTs lead to their critical roles in the formation and exacerbation of mucosal edema caused by increased microvascular permeability and leakage and the increased secretion of mucus, which are the main underlying mechanisms of airway obstruction. Early studies demonstrated that LTC~4~ and LTD~4~ could induce intense vascular constriction and dose-dependent extravasation of macromolecules in the hamster cheek pouch ([@B126]). Later, LTE~4~ was shown to increase the vascular permeability by inducing the contraction of endothelial cells in guinea pigs ([@B292]). LTD~4~ has also been shown to mediate dose-dependent microvascular leakage and bronchoconstriction in guinea pigs ([@B57]). Studies using gene-modified mice confirmed the involvement of CysLTR~1~ and CysLTR~2~ in the CysLT-enhanced vascular permeability ([@B382]; [@B47]; [@B415]). LTRAs could reverse such effects of CysLTs in several studies, further demonstrating the involvement of CysLTRs ([@B434]; [@B57]). The effects of LTC~4~ and LTD~4~ in inducing mucus production in the airways in vitro and in vivo have also been well documented ([@B390]; [@B117]; [@B287]).

Although both CysLTR~1~ and CysLTR~2~ show expression in lung smooth muscle cells and eosinophils, CysLTR~1~ is considered to be the major target for the pathophysiological action of CysLTs in asthma. This was largely based on the results from clinical investigations in which CysLTR~1~-selective antagonists could reverse most of the detrimental effects of CysLTs ([@B264]; [@B82]). In contrast, several lines of evidence suggested that the activity of CysLTR~1~ is regulated by CysLTR~2~. [@B285] reported that CysLTR~2~ forms heterodimer with CysLTR~1~ and negatively regulates the mitogenic responses induced by CysLTR~1~. Another GPCR, GPR17, has also been shown to dampen the function of CysLTR~1~ ([@B383]).

B. Currently Used Leukotriene Receptor Antagonist Drugs and Their Pharmacological Properties {#s44}
--------------------------------------------------------------------------------------------

The current LTRAs used in the treatment of asthma and other inflammatory diseases specifically target CysLTR~1~. To date, three LTRAs, montelukast, pranlukast, and zafirlukast, are used in the clinics ([Fig. 5](#F5){ref-type="fig"}). Pranlukast was the first marketed LTRA worldwide, although it is mostly used in Japan ([@B30]). Zafirlukast was the first LTRA approved by FDA and used in the United States in 1990s, followed by the later approval of montelukast. All three compounds show high affinities for CysLTR~1~, although they exhibit different pharmacological actions in blocking the action of LTC~4~ and LTD~4~ ([@B513]).

The primary in vivo effects of LTRAs are the inhibition of bronchoconstriction and inflammation. [@B187] showed that LTRAs were more potent in reducing antigen-induced contraction of human lung parenchyma compared with other therapies, including PG synthase and receptor inhibitors and antihistamine reagents in in vitro assays. The anti-inflammatory effects of LTRAs have been well documented. At therapeutic concentrations, LTRAs reduce the generation of reactive oxygen species and the release of a number of inflammatory mediators ([@B141]). In fact, a large number of studies that examined the inflammatory effects of CysLTs and CysLTRs used LTRAs as competitors to reverse the inflammatory action of CysLTs.

Some studies suggested the involvement of CysLTR~1~-independent mechanisms for the anti-inflammatory action of LTRAs ([@B606]; [@B599]), which include the inhibitory effects of LTRAs on cyclic nucleotide PDEs, transcription factor nuclear factor-𝜅B, PGE~4~ synthase, and 5-LOX. However, the clinical significance of those mechanisms needs to be further elucidated.

### 1. Montelukast {#s45}

Montelukast is the most widely prescribed LTRA in the United States and Europe, and the clinical significance of LTRAs in asthma was largely established based on the studies with montelukast. In vitro studies indicate that montelukast is associated with low nanomolar affinities, and it can specifically block the binding of LTC~4~ and LTD~4~ to cells expressing CysLTR~1~ ([@B289]). The initial large-scale clinical evaluation of montelukast during the 1990s established its efficacy in asthma and led to its approval ([@B545]; [@B103]; [@B135]; [@B517]). Several comparative studies suggested that montelukast could improve asthma control, reduce the rate of asthma exacerbation, and protect against bronchoconstriction ([@B356]; [@B516]; [@B387]). One study also showed that montelukast provided significant clinical benefits in protecting against EIA ([@B356]).

Several studies have also compared montelukast to ICS because ICS is the first-line anti-inflammatory agent for asthma. Some of them showed a superior efficacy of low-dose ICS compared with montelukast, which may be associated with the involvement of patients with largely moderate-to-severe asthma ([@B351]; [@B74]). Later, in a small-scale study with patients with mild asthma, montelukast showed satisfying efficacy as a monotherapy with a clinically significant improvement of asthma control ([@B402]). Noticeably, in this study, montelukast was associated with a much higher compliance to asthma therapy compared with ICS. This may be particularly important for treating asthma in the elderly.

Montelukast is most often used as an add-on therapy instead of monotherapy ([@B398]). Early studies demonstrate that montelukast could provide additional benefits of improving symptoms and lung function when combined with ICS ([@B351]; [@B581]; [@B618]). However, later studies that compared montelukast with LABAs in combined use with ICS generated mixed results ([@B179]; [@B618]; [@B140]). It has been suggested that ICS with LABAs may provide higher efficacy compared with ICS with montelukast for short-term use, whereas these two methods resulted in similar outcomes for long-term use ([@B290]). Montelukast is associated with a higher safety profile and a lower rate of side effects compared with LABAs in long-term use ([@B290]). The higher safety profile of montelukast may be especially beneficial for treating asthma in children and adolescents ([@B55]). In fact, all three LTRAs can be used in pediatrics with controlled dosages.

Montelulast as a representative LTRA has been studied in a number of asthma phenotypes, in which the level of inflammatory CysLTs is elevated due to specific factors or conditions such as smoking and exercise. Asthma patients who smoke may develop resistance to ICS ([@B601]), and there is one study conducted in the 1990s demonstrating that habitual smoking is associated with increased levels of CysLTs ([@B172]). In a small-scale clinical study on mild asthma patients with self-reported smoking, the response to ICS was attenuated and montelukast as a monotherapy resulted in a greater improvement in lung function ([@B352]). A later clinical study with over 300 patients showed that although patients with a history of smoking less than 11 years tended to have more benefits with ICS, montelukast seemed to offer more benefits for patients with a long history of smoking (\>11 years) ([@B501]). Second, EIA or exercise-induced bronchoconstriction is frequent in children and especially in athletes. One study showed that montelukast could attenuate exercise-induced bronchoconstriction in children with asthma ([@B308]). Although montelukast showed a lower efficacy compared with LABAs in treating EIA in one study ([@B508]), it is associated with less side effects and does not lead to tolerance. For LABAs, if taken daily, tolerance may develop to the protective effects in EIA ([@B8]). Third, montelukast has been studied in the treatment of aspirin-induced asthma (AIA). Aspirin and other nonsteroidal anti-inflammatory drugs can inhibit the activity of cyclooxygenase and thus facilitate the metabolism of AA through 5-LOX pathways to generate excessive CysLTs. It was estimated that about 10% asthma patients on nonsteroidal anti-inflammatory drugs may develop AIA ([@B398]). One study showed that aspirin-sensitive or aspirin-intolerant asthma patients had a greater level of LTE~4~ compared with the control group of asthma patients ([@B109]). Another small-scale clinical trial showed promising results of montelukast in treating AIA, in which montelukast as an add-on drug could further improve pulmonary function and asthma-specific quality of life over what could be achieved by ICS ([@B129]). Fourth, obesity is another factor that can result in systemic inflammation associated with adipose tissues, which includes the generation of CysLTs. One clinical study examined the relationship of asthma and body mass index and showed that in general the response of asthma patients to ICS decreased with increased body mass index, but the response to montelukast remained stable ([@B199]). This may be an example of where asthma endotype plays a role in that obesity-related asthma does not have a typical type 2 cytokine profile, which is most responsive to ICS therapy.

### 2. Pranlukast {#s46}

In vitro studies showed that pranlukast is a potent and selective antagonist for CysLTR~1~ that could dose-dependently reverse the effects of LTC~4~ and LTD~4~ on isolated human bronchial smooth muscle ([@B434]; [@B659]). In one study, pranlukast showed lower potency in competing with the binding of ^3^H-LTC~4~ to CysLTR~1~ compared with montelukast ([@B513]). Consistently, for the clinical use, the dosage of pranlukast (∼200 mg once or twice daily) is much higher than the dosage of montelukast (∼10--20 mg once daily) for treating asthma in adults.

Animal studies with pranlukast confirmed its potent anti-inflammatory and antibronchospasm effects as a result of specifically blocking CysLT binding ([@B455], [@B454]; [@B434], [@B435]; [@B341]; [@B57]). The anti-inflammatory effects of pranlukast on eosinophils were examined and confirmed in a few clinical trials ([@B256]; [@B273]; [@B661]). In several studies, pranlukast showed significant efficacy in reversing bronchoconstriction caused by various stimuli, including LTD~4~, dust mite, aspirin, exercise, and even alcohol ([@B1]; [@B227]; [@B274]; [@B586]; [@B673]; [@B427]; [@B452], [@B453]). Some other studies also showed the effectiveness of pranlukast in reducing bronchial hypersensitiveness, another important feature of asthma, caused by various factors ([@B437]; [@B274]; [@B672]; [@B661]; [@B533]). Because the current first-line method for treating asthma is ICS or ICS plus LABAs, a number of recent studies tested whether pranlukast could provide additional clinical benefits when used with ICS or ICS plus LABAs. These studies demonstrated that pranlukast could further reduce eosinophilic airway inflammation and thus might further improve lung function ([@B460]; [@B666]). Indeed, a long-term follow-up study suggested that pranlukast provided benefits of improving lung function that lasted for more than 1 year if taken daily ([@B664]).

Similar to montelukast, pranlukast has been studied in a number of clinical trials to examine its effects in different asthma phenotypes. The efficacy of pranlukast compared with placebo or antihistamine was confirmed in a few clinical trials with mild to moderate adult asthma patients ([@B30]; [@B31]; [@B671]). Several small-scale studies also showed that pranlukast was effective for patients with moderate to severe asthma treated with ICS or who are refractory to ICS ([@B669]; [@B323]; [@B609]). The clinical efficacy of pranlukast in pediatric asthma was examined and proven in Japan ([@B307]). One study demonstrated that pranlukast monotherapy showed a clinical efficacy comparable to that of ICS monotherapy for elderly patients with mild asthma ([@B257]).

### 3. Zafirlukast {#s47}

Although described as a selective and competitive antagonist of CysLTR~1~ ([@B328]), zafirlukast is a relatively less studied LTRA compared with montelukast and pranlukast. Early studies that demonstrated its ability to reduce eosinophil-related inflammation and bronchoconstriction were conducted in animals ([@B328], [@B329]). One in vitro study showed that zafirlukast is as potent as montelukast in blocking the binding of ^3^H-LTD~4~ to CysLTR~1~ in isolated human lung parenchyma ([@B513]). The same study also demonstrated that, unlike montelukast and pranlukast, zafirlukast was unable to interfere with the binding ^3^H-LTC~4~ in the same experimental settings, suggesting a potentially different pharmacological action of zafirlukast compared with montelukast and pranlukast, such as a different binding site on CysLTR~1~. However, the underlying mechanism is not clear ([@B155]).

The efficacy of zafirlukast in asthma has been confirmed in a number of clinical trials ([@B155]). Compared with placebo, zafirlukast provided sustained clinical benefits for patients with mild to moderate asthma in a large-scale clinical study ([@B180]). As a monotherapy, zafirlukast also showed significant benefits for patients with severe and persistent asthma ([@B309]). The effects of zafirlukast as an add-on therapy were also evaluated. One study showed that zafirlukast could improve lung function and reduce the risk of exacerbation for patients who were already on high-dose ICS ([@B624]). However, a few studies showed that zafirlulast was less effective as an add-on drug compared with salmeterol, a LABA, in combined use with ICS ([@B73]; [@B441]). The clinical benefits, safety, and tolerability of zafirlukast for children with mild to moderate asthma were evaluated and proven in several studies ([@B478]; [@B155]).

C. Structural Insights into Drug Action {#s48}
---------------------------------------

Montelukast, pranlukast, and zafirlukast exhibit distinct chemical scaffolds with limited similarity ([Fig. 5](#F5){ref-type="fig"}). This is in contrast to *β*~2~-agonists, which share a relatively conservative chemical feature. The first marketed LTRA, pranlukast, was developed based on compounds from random screening ([@B436]; [@B50]). The structure and activity relationship (SAR) studies for developing pranlukast were done in reference to the structure of endogenous CysLTs. Other research efforts for developing antagonists of CysLTRs were focused on direct modifications of CysLTs ([@B50]). The aims were to modify the unstable polyene chain of CysLTs and to switch the agonists into antagonists. Such efforts led to the discovery of a series of lead compounds, which further led to the development of montelukast and zafirlukast through extensive SAR studies. Although the overall chemical structures of LTRAs are distinct from CysLTs, in montelukast, there is a cyclopropyl--acetic acid group attached to the main chain through a sulfanyl group, mimicking the Cys-Gly peptide moiety of LTD~4~.

To date there are no high-resolution structures of CysLTRs that have been solved experimentally. CysLTRs belong to the *δ*-subgroup of class A GPCRs, whereas other leukotriene receptors and PG receptors belong to the *α*- and *γ*-subgroups ([@B183]). This may suggest a novel mechanism for CysLTRs to recognize endogenous lipid ligands compared with other eicosanoid GPCRs. The closest phylogenetic neighbors of CysLTRs with solved structures are protease-activated receptors 1 and 2 (PAR1 and PAR2) ([@B676]; [@B104]). Two purinergic receptors, P2Y~12~ and P2Y~1~, with solved structures are also closely related to CysLTRs ([@B679],[@B680], [@B677]). However, those structures revealed very diverse binding modes of antagonists. It seems that antagonists of PARs and purinergic receptors could recognize multiple ligand-binding sites inside or on the surface of the 7TM bundle. Therefore, it is difficult to gain insight into the binding of LTRAs to CysLTR~1~ based on the published structures of GPCRs in the *δ*-subgroup. Because currently used LTRAs are with diverse chemical structures with no obvious conserved features, it is likely that they engage in different modes of interactions with the receptor or even occupy different ligand-binding sites. Considering the partial chemical similarity of montelukast with LTD~4~, montelukast may occupy the same orthosteric site as LTD~4~.

Although there is no structure of CysLTR~1~ bound to montelukast, there is one structure of montelukast bound to the xenobiotic metabolizing enzyme, cytochrome P450 2C8 ([@B543]) ([Supplemental Material 1-PDB ID 2NNI](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). In this structure, montelukast showed a tripartite binding mode. The three branches of montelukast occupy three different binding pockets. The authors suggested that the high complementarities of montelukast to the ligand-binding cavity in shape, size, hydrophobicity, and polarity lead to the high affinity of montelukast for this enzyme. It will be interesting to see whether montelukast adopts a similar binding mode for CysLTR~1~. Another study reported structural modeling of CysLTR~1~ bound to LTRAs ([@B27]). The authors further used this structure to do virtual screening to discover new CysLTR~1~ antagonists. The results predicted a ligand-binding mode in which the ligand formed extensive interactions with the extracellular regions of TM4, TM5, TM7, as well as ECL2.

V. Potential G Protein--Coupled Receptor--Targeting Drugs for Asthma in Late-Stage Clinical Trials {#s49}
==================================================================================================

A. New G Protein--Coupled Receptor Targets for Developing Asthma Drugs {#s50}
----------------------------------------------------------------------

Although current therapeutic methods including the combined use of ICS with LABAs are highly effective in most asthma patients, there is still a need for developing new therapies ([@B2]; [@B35]; [@B65]; [@B166]; [@B214]; [@B685]). There are a number of proinflammatory mediators, including PGs, leukotrienes, and chemokines, which play important roles in the pathogenesis of asthma and bind GPCRs. Therefore, there have been continuous research efforts in the past several decades in developing drugs targeting these GPCRs to better control inflammation for treating asthma. Although some of those efforts were successful, such as the development of LTRAs, many of them were not.

Besides CysLTs, another leukotriene, LTB~4~, which does not contain a glutathione moiety, has been implicated in the inflammatory process of asthma ([@B195]). There are two GPCRs for LTB~4~, leukotriene receptor (BLT~1~) as the high-affinity receptor and BLT~2~ as the low-affinity receptor. BLT~1~ is highly expressed in CD8^+^ T cells and DCs and promotes chemotaxis and generation of Th2 cytokines ([@B660]; [@B15]). The effects of LTB~4~--BLT~1~ signaling axis in AHR have been proven in a number of animal models ([@B619]; [@B411]; [@B596]). Although some studies showed efficacy of BLT~1~ antagonists in rodent and nonhuman primate models of asthma ([@B612]; [@B247]; [@B636]), clinical trials with BLT~1~ antagonists all failed or were not being pursued further ([@B248]).

Over 50 different chemokines can be divided into four groups: CXC, CC, C, and CX3C ([@B530]; [@B88]). They signal through more than 20 GPCRs as chemokine receptors to result in the chemotaxis and recruitment of immune cells to initiate various inflammatory processes ([@B88]). In addition, chemokine receptors also play important roles in lung biology such as repair and remodeling ([@B608]). Despite intensive research efforts, very few drugs targeting chemokine receptors have made it to the market, and none of them are currently used for asthma ([@B88]). Among all chemokine receptors, CCR3 is the primary chemokine receptor expressed on eosinophils and T~H~2 cells and mediates the migration and activation of those immune cells ([@B479]; [@B88]). Therefore, it has long been suggested to be a potential drug target for asthma. The development of small-molecule antagonists of CCR3 as drugs has been proven difficult. Instead, an antisense nucleotide drug ASM8, which can downregulate CCR3, has been developed and studied in a few clinical trials ([@B480]). Several studies showed that ASM8 could attenuate allergen-induced eosinophilic inflammation in asthmatic patients ([@B191], [@B192]; [@B268]). However, to the best of our knowledge, further clinical development of ASM8 for treating asthma was not reported. Another chemokine receptor, CXCR2, has been shown to regulate the production of type 2 cytokines during inflammation ([@B395]). One study suggested a critical role of CXCR2 in pathogen-induced persistent asthma in mice ([@B547]). A number of CXCR2 antagonists have been studied clinically. Although one study with compound SCH527123 showed that CXCR2 antagonism could reduce neutrophils in patients with severe asthma ([@B433]), another phase II study with compound AZD5069 showed no effects in reducing the frequency of exacerbations in patients with uncontrolled severe asthma, raising the question about the roles of CXCR2 in severe asthma ([@B457]). To the best of our knowledge, currently there are no active late-stage clinical trials with chemokine receptor antagonists for asthma registered on [clinicaltrials.gov](http://clinicaltrials.gov).

In humans, there are nine GPCRs characterized to date for the endogenous PGs D~2~, E2, F~2~, I~2~, and thromboxane A~2~ (PGD~2~, PGE~2~, PGF~2~, PGI~2~, and TXA~2~) ([@B652]). Although a number of PG receptors have been shown in vitro and in animal models to play important roles in inflammation ([@B482]), to date only compounds that target one PG receptor, PGD~2~ receptor 2 (DP2, also named CRTH2), have advanced to phase III clinical trials for treating asthma.

The roles of GPCRs for PG, leukotriene, and chemokines in asthma have been reviewed in details by numerous papers elsewhere. In this work, we hope to provide a review of drug candidates targeting DP2 as a potential new class of asthma drugs in late-stage clinical trials. We will also review a few compounds in late-stage trials that act on existing GPCR targets for asthma.

B. Prostaglandin D~2~ Receptor 2 and Its Antagonists {#s51}
----------------------------------------------------

### 1. The Roles of Prostaglandin D~2~ Receptor 2 in Asthma {#s52}

AA can be metabolized by COX and PG synthases to generate various PG molecules ([@B482]). PGD~2~ is synthesized by the PGD synthase from its precursor PGH~2~. In turn, PGD~2~ is further metabolized to other PGs, through enzymatic processes, which include 15-deoxy-Δ^12,14^-PGD~2~, 13,14-dihydro-15-keto-PGD~2~,11*β*-PGF~2*α*~, and Δ^12^-PGD~2~, and nonenzymatically to PGJ~2~ and corresponding metabolites. During inflammatory processes, PGD~2~ is primarily produced by mast cells as well as other immune cells, including eosinophils, macrophages, DCs, and T~H~2 cells ([@B147]). Two GPCRs mediate the cellular functions of PGD~2~: PGD~2~ receptor 1 and 2 (DP1 and DP2). DP2 is also commonly named as CRTH2, which is short for 3chemoattractant receptor-homologous molecule expressed on T~H~2 cells ([@B430]). High concentrations of PGD~2~ can also act on the thromboxane receptor (TP) ([@B116]). Interestingly, DP1 and DP2 are phylogenetically distant, even though they recognize the same endogenous ligand. DP1 is closely related to other PG receptors, whereas DP2 is more akin to a group of chemoattractant GPCRs such as the receptors for anaphylatoxins C5a and C3a, formyl peptide receptors (FPRs), and BLTs ([@B183]). Also, DP1 mainly couples to G~s~ family to stimulate cAMP production, whereas DP2 couples to G~i~ family to reduce cAMP levels and induce Ca^2+^ responses.

The signaling of DP1 and DP2 in response to PGD~2~ plays different roles in inflammation ([@B238]; [@B594]; [@B326]; [@B490]). DP1 is mainly expressed in vascular smooth muscle cells, platelets, and DCs. DP1 signaling contributes to the pathologic changes of blood flow in inflammation and regulates the polarization of T~H~2 cells ([@B490]). The role of DP1 in inflammation is not completely understood and is controversial. A few studies suggested that the signaling of DP1 could inhibit the chemotaxis and activation of eosinophils, basophils, and DCs, therefore eliciting anti-inflammatory actions ([@B9]). Several in vivo studies showed that DP1 activation could be either proinflammatory or anti-inflammatory depending on different experimental methods, pathologic conditions, or pharmacological tools used ([@B397]; [@B229]; [@B9]; [@B13]; [@B459]; [@B326]). In contrast, DP2 signaling has been consistently shown to be proinflammatory. DP2 is highly expressed in T~H~2 cells, including ILC2 cells, eosinophils, and basophils, and regulates the chemotaxis of those cells ([@B431]; [@B250]; [@B97]; [@B658]). In the past two decades, a plethora of studies have confirmed the critical role of DP2 signaling in inflammation.

PGD~2~-induced DP2 signaling has been shown to upregulate the production of type 2 cytokines, including IL-4, IL-5, and IL-13 by T~H~2 cells and ILC2 cells through a PGD~2~ dose-dependent manner in in vitro studies ([@B657], [@B658]). It can also promote the chemotaxis and migration of T~H~2 cells, ILC2 cells, and eosinophils ([@B242]; [@B219]; [@B655], [@B658]). [@B656] showed that PGD~2~ could promote prolonged inflammation by inhibiting apoptosis of T~H~2 cells through DP2. The activation of eosinophils by DP2 has also been demonstrated in a number of studies. Those studies showed that PGD~2~ signaling through DP2 on the surface of eosinophils could lead to shape change and promote degranulation and cytokine production ([@B196]; [@B590]; [@B539]). In addition, type 2 cytokines induced by DP2 signaling can have positive effects on the activation and migration of eosinophils, further contributing to excessive inflammation. All of those studies indicated a strong linkage of DP2 to inflammation, especially eosinophil-associated inflammation.

Additional studies have demonstrated a critical role of DP2 in asthma. Early studies demonstrated that allergen challenge could lead to the release of PGD~2~ into human airways, especially in asthma patients ([@B424]; [@B645]). [@B165] showed that PGD~2~ and DP2 pathway is upregulated in patients with severe and T~H~2-high asthma. PGD~2~ and DP2 pathway has also been shown to mediate respiratory virus-induced enhancement of inflammation and AHR ([@B562]). The development of potent and specific DP2 antagonists has allowed studies of DP2 antagonism in tissues, animals, and patients, which provided direct evidence for the potential use of DP2-targeting therapies for treating asthma ([@B339]).

### 2. Prostaglandin D~2~ Receptor 2 Antagonists {#s53}

The first nonlipid DP2 antagonist to be discovered was ramatroban (also named BAY-u3405), which was initially developed as a drug antagonizing TP ([@B585]; [@B275]) ([Fig. 6](#F6){ref-type="fig"}). Although ramatroban is a nonselective DP2 antagonist, it is selective for DP2 over DP1. Studies using ramatroban confirmed that PGD~2~-induced eosinophilic inflammation in the airways was mediated by DP2, but not DP1 ([@B561]). Later, a number of potent and selective DP2 antagonists were soon developed based on SAR studies of ramatroban involving research groups in academia and industry ([@B378]). Those include a potent DP2 antagonist, CAY10471 (also named TM30089), which showed insurmountable antagonism on DP2 in in vitro studies ([@B394]). It was then used in studies based on a mouse asthma model, which for the first time demonstrated the in vivo efficacy of DP2 antagonists in reducing eosinophilic inflammation in the airways ([@B614]). CAY10471 was also shown to inhibit chemotaxis of eosinophils from guinea pig bone marrow tissues ([@B531]).

![Chemical structures of PGD~2~ and CRTH2 antagonists.](pr.118.016899f6){#F6}

During the 2000s, a number of DP2 antagonists were pushed into clinical studies for the treatment of asthma. A small-scale clinical study using compound OC000459 as a potent DP2 antagonist provided the first clinical evidence for the effectiveness of antagonizing DP2 in reducing airway inflammation and improving symptoms in patients with moderate to severe asthma ([@B29]). Later, a larger clinical study using a lower dose of OC000459 again proved its efficacy in improving symptoms and lung function in asthma ([@B491]). Another study showed that OC000459 could effectively inhibit allergic inflammation in asthma patients ([@B566]). In all of those clinical studies, asthma patients without ICS treatment were included. Further clinical development of OC000459 is ongoing ([@B339]).

Other DP2 antagonists that have gone through clinical studies include BI 671800 ([@B182]), AZD 1981 ([@B542]), AMG 853 ([@B368]), setipiprant ([@B185]), and fevipiprant ([@B590]) ([Fig. 6](#F6){ref-type="fig"}). The results from those clinical studies were mixed. BI 671800 showed an effect of slightly improved lung function in steroid-naive asthma patients, but failed to show additional effects as an add-on therapy to ICS ([@B226]; [@B407]). The authors suggested that it might be due to the insufficient inhibition of DP2 signaling by BI 671800 even at a high dose. Two phase II clinical trials with AZD 1981 showed improved lung function and symptoms in asthma patients withdrawn from ICS treatment or patients with uncontrolled asthma despite ICS treatment ([@B337]). However, another study indicated that AZD 1981 failed to show any clinical benefit as an add-on therapy to ICS plus LABA in patients with allergic asthma ([@B41]). AMG 853 is a unique DP2 antagonist because it also antagonizes DP1. Even with a dual action on DP2 and DP1, AMG 853 did not show any benefit in improving lung function or symptoms as an add-on therapy to ICS in patients with poorly controlled moderate to severe asthma ([@B76]). For setipiprant, one small-scale study showed that it could reduce allergen-induced late asthmatic response in patients with allergic asthma, consistent with the findings for other DP2 antagonists ([@B142]). Fevipiprant (also named QAW039) is the most advanced DP2 antagonist in clinical trials ([@B646]). One phase II trial showed that fevipiprant could reduce eosinophilic inflammation in a group of patients with uncontrolled moderate to severe asthma despite ICS treatment ([@B204]). This was also the first study to show a positive effect of a DP2 antagonist in improving airway remodeling. Consistently, fevipiprant has been demonstrated to be efficacious in improving the end point of forced expiratory volume in patients with uncontrolled asthma who were on low-dose ICS ([@B39]). Another phase II study showed that fevipiprant could improve lung function and asthma control in a small group of patients with severe asthma that was not well controlled by ICS plus LABA ([@B162]). Currently, fevipiprant is in several phase III clinical trials ([@B646]). If successful, it will be the first small-molecule asthma drug with a new mechanism over a decade.

Fevipiprant has been suggested to be a slow-dissociating DP2 antagonist based on radioactive ligand-binding assays ([@B590]). Although the half-life of dissociation of fevipiprant determined in those assays was only 14.4 minutes, it was still significantly slower than AZD 1981. OC000459 has been shown to be a highly reversible antagonist in the presence of PGD~2~ ([@B492]). Although highly speculative, it is possible that the receptor residence time is an important factor affecting the clinical efficacy of DP2 antagonists in asthma. During inflammation, locally generated PGD~2~ by mast cells and other immune cells could be at a high concentration, which may overcome the antagonistic action of highly reversible DP2 antagonists even though their concentrations in the plasma stay high. In this regard, for DP2 antagonists, a slow dissociation rate and long-lasting action may translate into a superior in vivo efficacy. Similar to such speculation, it has been suggested that for another GPCR, the C5a receptor, signaling of which promotes strong inflammatory responses, receptor residence time is more important than drug-likeness and bioavailability in determining the efficacy of its antagonists ([@B554]). For DP2, one compound named LAS191859 was reported to be an extremely slow-dissociating antagonist with a half-life of dissociation more than 20 hours ([@B77]). The authors showed that the long receptor residence time led to a long-lasting in vivo efficacy of LAS191859 even when the plasma level of the compound was low.

### 3. Structural Insights into the Action of Prostaglandin D~2~ Receptor 2 Antagonists {#s54}

Nearly all DP2 antagonists contain a carboxylate group like PGD~2~, which is believed to be a major pharmacophore. In many of them, the carboxylate group is attached to an aromatic group with one methyl group in between ([@B493]). [@B394] showed that the spacer between the carboxylate and the aromatic group of CAY10471 was important for ligand potency. Other than the carboxylate group, DP2 antagonists seem to exhibit a vast chemical diversity ([@B493]; [@B448]).

Recently, two crystal structures of human DP2 bound to two antagonists, CAY10471 and fevipiprant, were reported, which revealed the molecular details for the binding of both ligands ([@B634]) ([Fig. 7](#F7){ref-type="fig"}) ([Supplemental Material 1-PDB IDs 6D26 and 6D27](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)). In the structures, the N-terminal region adopts a well-folded structure stabilized by a disulfide bond with TM5. It results in a semi-occluded ligand-binding pocket and restricts the access to the ligand-binding pocket through the extracellular region. There is a gap between the extracellular regions of TM1 and TM7 as the only open end of the ligand-binding pocket, which was proposed to be the ligand entry port for endogenous ligands as well as synthetic antagonists. In the structures, the carboxylate group in both antagonists as the head group engages in a polar interaction network with several polar residues buried deeply in the ligand-binding pocket. Interestingly, a majority of residues in the ligand-binding pocket are actually aromatic residues, which form extensive hydrophobic and *π*-stacking interactions with the central aromatic group in CAY10471 or fevipiprant.

![Orthosteric ligand-binding site in CRTH2. The crystal structures of human CRTH2 bound to fevipiprant (left, [Supplemental Material 1-PDB ID 6D26](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)) and CAY10471 (right, [Supplemental Material 1-PDB ID 6D27](http://pharmrev.aspetjournals.org/lookup/suppl/doi:10.1124//pr.118.016899/-/DC1)) revealed the molecular details of ligand binding in the orthosteric ligand-binding site.](pr.118.016899f7){#F7}

Although the overall binding poses of CAY10471 and fevipiprant are similar, their tail groups adopt different conformations and interact with different parts of the receptor. As a result, the tryptophan residue W283 of DP2 shows different conformations ([@B634]). In addition, docking of ramatroban, which shares a high chemical similarity with CAY10471, showed that the carboxylate group in ramatroban forms polar interactions with a different set of residues, resulting in a different binding pose of ramatroban compared with CAY10471. This explains the lower potency of ramatroban compared with CAY10471 ([@B394]). Those observations imply a certain flexibility of the ligand-binding pocket, which should be an important consideration for structure-based drug design studies. Another interesting feature revealed by the structures is that there are small molecules bound at the ligand entry port. This feature allowed the authors to propose a potential mechanism for the binding process of PGD~2~ ([@B634]). The authors also suggested that the ligand entry port in DP2 might provide an additional space for designing new DP2 antagonists. The molecular mechanism underlying receptor residence time for DP2 antagonists is not clear based on the crystal structures. A structure of DP2 with LAS191859 and MD simulation studies may provide additional insights and help with designing new long-lasting DP2 antagonists.

C. Potential Asthma Drugs Acting on Existing Asthma Targets {#s55}
-----------------------------------------------------------

Fixed-dose combinations of inhaled corticosteroids and LABAs have been commonly recommended for moderate to severe asthmatic patients. To improve the patients' adherence and the control of disease, there has been considerable interest for the next generation of inhaled *β*~2~-agonists, maintaining over 24 hours of bronchodilation thus limited to daily use (ultra-LABAs). Although a few ultra-LABAs have already hit the market, at present there are still several ultra-LABAs in different stages of clinical development, such as abediterol and bedoradrine ([Fig. 8](#F8){ref-type="fig"}).

![Chemical structures of two potential asthma drugs acting on *β*~2~AR: (A) abediterol, (B) bedoradrine.](pr.118.016899f8){#F8}

### 1. Abediterol {#s56}

The structure of abediterol contains both the lipophilic tail moiety similar to that of salmeterol and vilanterol and the quinoline-2-one moiety similar to that of indacaterol and olodaterol ([@B12]). Abediterol is a full agonist at the human *β*~2~AR \[Emax (maximum effect) = 91% ± 5% of the maximal effect of isoproterenol\]. The potency and onset of action of abediterol in isolated human bronchi (EC~50~ = 1.9 ± 0.4 nM; onset t~1∕2~ = 7--10 minutes) are similar to those of formoterol, whereas its duration of action (half-life = 690 minutes) is more prolonged. In dogs, abediterol showed a greater safety margin than salmeterol and formoterol (5.6 vs. 3.3 and 2.2). Selectivity for *β*~2~ over other *β*-adrenergic receptor subtypes determined by calculating *β*~1~/*β*~2~ and *β*~3~/*β*~2~ IC~50~ and EC~50~ ratios indicated that both salmeterol and abediterol have high selectivity profiles over the human *β*~1~AR and *β*~3~AR, better than formoterol. In general, the preclinical data of abediterol suggested that it is a potent and selective *β*~2~-agonist with rapid onset and long duration of action, together with a favorable cardiovascular safety profile, suitable for once-daily dosing in humans.

The first in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of abediterol at once-daily doses of 5, 10, 25, or 50 *µ*g showed potent, rapid, and sustained bronchodilatory effects of this drug in healthy male subjects ([@B605]; [@B413]). A dose-dependent increase of adverse events was observed, the most frequent being palpitations, tremor, nausea, and asthenia; most were mild in intensity and resolved without the need for intervention. This phase I study suggested that abediterol at measured doses is generally safe and well tolerated. It increases airway conductance and decreases airway resistance for up to 36 hours after a single dose, consistent with preclinical data. In a subsequent phase II study conducted in 25 male patients with mild-to-moderate persistent asthma, all doses of abediterol demonstrated statistically significant improvements in lung function compared with both placebo and salmeterol ([@B45]). To further evaluate lower abediterol doses, in a second phase II study, abediterol 0.313, 0.625, 1.25, and 2.5 *µ*g doses were evaluated and compared with salbutamol and placebo in male and female patients with persistent asthma ([@B568]). Patients who received abediterol at these lower doses experienced rapid and sustained bronchodilation, with statistically significant benefits compared with placebo and a magnitude of effect comparable with salbutamol for all but the lowest abediterol dose. This result is also consistent with a later phase II study assessing the efficacy, safety, and tolerability of abediterol at 2.5, 5, and 10 *µ*g doses, given once daily for 7 days in patients with stable, persistent asthma ([@B46]). These results suggest that abediterol is a promising new once-daily LABA for the treatment of asthma and COPD. The results of the conducted phase III studies are not available at this time.

### 2. Bedoradrine {#s57}

Bedoradrine (KUR-1246, MN221) is a novel *β*~2~-agonist with a chemical structure similar to other classic *β*~2~-agonists. It has a tetrahydronaphthol substitution in the terminal amino group of the ethylamine side chain. It is similar to other LABAs by having a catechol-like group as the head and an ethanolamine group as the middle moiety. The remarkable characteristic of bedoradrine is the tetrahydronaphtyl substitution in the terminal amino group, which is believed to be essential for the potent activity and high selectivity of bedoradrine over other *β*-adrenergic receptor subtypes ([@B312]).

Bedoradrine was initially developed as a tocolytic agent. In vitro receptor binding and cell activation studies in animals have demonstrated that bedoradrine has a high selectivity for *β*~2~ over other *β*-adrenergic receptor subtypes ([@B322]; [@B270]). Later, bedoradrine entered in clinical development for the treatment of acute asthma exacerbations via intravenous delivery. Two phase I clinical studies ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT01013142, NCT01551316) evaluated the safety, tolerability pharmacokinetics, and preliminary bronchodilator efficacy of bedoradrine in patients with COPD. Two subsequent phase II studies assessed the safety and efficacy of bedoradrine in escalating doses and a fixed dose in patients with mild-to-moderate asthma and moderate-to-severe asthma, respectively ([@B396]). Another randomized, placebo-controlled phase II study evaluated the safety and efficacy of intravenous bedoradrine added to the standard therapy in patients with asthma exacerbations ([@B260]). It is still unclear whether intravenous bedoradrine can significantly improve lung function in severe, acute asthma exacerbations in addition to standard therapy; however, its use was associated with significantly improved dyspnea scores ([@B396]; [@B260]). Results from these studies demonstrated that bedoradrine is safe and without significant adverse effects in bedoradrine-treated patients ([@B396]; [@B10]). The current safety profile of bedoradrine and the potential for increased selectivity and reduced side effects in humans, as well as the intravenous route of administration, support further clinical development of bedoradrine as a novel therapy for asthma.

VI. Future Perspectives {#s58}
=======================

Although in most patients asthma can be well controlled with current available therapeutics, there are still a large number of asthma patients who require more effective therapies. Our new understanding of the heterogeneity of asthma also suggests the need for developing novel therapeutics for certain types of asthma, including the nonatopic, T~H~2 low, or obesity-related asthma endotypes. Despite such demand, drug development in the past two decades for asthma has been slow. The current mainstream treatment methods for asthma, which include the combined use of ICSs, LABAs, and LAMAs, were established more than 15 years ago. Biologic drugs such as antibodies targeting IL-5 and IgE were introduced as a new class of anti-inflammatory therapeutics recently, which provided additional add-on options for asthma patients with certain phenotypes ([@B483]). Biologics are also under development for the inhibition of IL-13, IL-4, and other cytokines.

In this study, we will review GPCR-targeting ligands that have potential as new asthma drugs, with a focus on those that have entered clinical trials ([Fig. 9](#F9){ref-type="fig"}). However, we would also like to point out that there are a number of other promising GPCR modulators in the early development for asthma. Those include bitter taste receptor agonists such as saccharin, chloroquine, and quinine ([@B138]; [@B209]); calcium-sensing receptor antagonists ([@B665]); and specialized proresolving lipid mediators (SPMs) ([@B37]). They may as well offer exciting opportunities for the development of novel asthma therapeutics ([@B487]). In addition, we will also review new opportunities in GPCR drug development, including the structure-based drug design and the development of GPCR-targeting antibodies.

![Chemical structures of three GPCR-targeting ligands that are in early stage of development for asthma. (A) AZD8871, (B) CVT-6883, and (C) toreforant.](pr.118.016899f9){#F9}

A. G Protein--Coupled Receptor Drugs in Early Stage of Development {#s59}
------------------------------------------------------------------

### 1. AZD8871 as a Dual-Action Ligand of Muscarinic Receptors and β~2~-Adrenergic Receptor {#s60}

Dual-action therapeutic methods combining LAMAs and LABAs have been introduced to achieve better efficacy compared with monotherapy with either class alone ([@B526]). Bifunctional molecules that represent a fusion of established LAMAs and LABAs in one molecule by an inactive spine are known as muscarinic antagonists/*β*~2~-agonists (MABAs). Several MABAs, such as batefenterol (GSK961081), AZD2115, and AZD8871, are currently in clinical development, aiming to achieve a synergy between the pharmacological actions of LAMAs and LABAs. MABAs are also expected to provide a potentially simpler technical and clinical development pathway compared with the dual therapy ([@B40]; [@B468]; [@B214]).

Although MABAs were designed to occupy the orthosteric sites in *β*~2~AR and MRs, their pharmacological action may be more complex. Pharmacological studies on MABA THRX-198321 suggested that the muscarinic antagonist moiety may occupy an allosteric site in *β*~2~AR and the *β*~2~-agonist moiety may occupy the allosteric site in MRs ([@B580]). The exosite in the extracellular vestibule of *β*~2~AR ([@B392]) could be the allosteric site for THRX-198321. Therefore, THRX-198321 acts as a bivalent ligand, not just a bifunctional ligand, on *β*~2~AR and MRs in a way that it occupies both orhosteric and allosteric sites. As a result, its affinities are higher at both receptors relative to the monovalent fragments. Whether other MABAs exhibit similar pharmacological properties needs further investigation.

AZD8871 (LAS191351) is an inhaled long-acting MABA under development for the treatment of COPD and asthma. To date, several phase I and II clinical studies have been completed with AZD8871 on COPD subjects ([@B567]), whereas the first phase I clinical trial for asthma was recently completed in 2018 ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT02573155). This particular trial was a randomized, placebo-controlled two-part study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD8871 delivered by inhalation in asthmatic and COPD subjects. In conclusion, AZD8871 was safe and well tolerated, and it showed sustained bronchodilation at different doses. It delivered clinically meaningful improvement of symptoms and was superior to the reference agents, indacaterol (ultra-LABA) and tiotropium (LAMA), at a high dose (1800 *µ*g). Further clinical development of AZD8871 in larger studies is required to evaluate its potential as a novel treatment option for asthma and COPD.

### 2. CVT-6883 as an Antagonist of Adenosine A2B Receptor {#s61}

From the 1980s, adenosine has been found to induce bronchoconstriction in patients with asthma and to increase the concentrations of proinflammatory mediators released from mast cells such as histamine, tryptase, LTC~4~, and PGD~2~ ([@B125]; [@B123]). This suggested that adenosine may cause bronchoconstriction through mast cell activation ([@B497]; [@B253]). In addition, higher concentrations of adenosine have been detected in the bronchoalveolar lavage fluid and the exhaled breath condensate of patients with asthma ([@B154]; [@B265]). This suggested that adenosine may also function as a paracrine mediator for the inflammatory responses in the lung.

The effects of adenosine are mediated through a group of class A GPCRs comprising four subtypes, named as A~1~, A~2A~, A~2B~, and A~3~ adenosine receptors ([@B461]). The A~2B~ receptor has been suggested to play an important role in the pathophysiology of asthma by mediating airway reactivity and modulating chronic inflammatory responses in the lung, which can be inhibited by selective antagonists of the A~2B~ receptor ([@B173]; [@B174]; [@B532]; [@B682], [@B683]).

The compound CVT-6883 is a potent and selective A~2B~ receptor antagonist. It has a much greater affinity for the A~2B~ receptor (Ki = 22 nM) than for other adenosine receptors ([@B161]). In animal studies, CVT-6883 was found to be as effective as monteleukast as it decreased the number of inflammatory cells in bronchoalveolar lavage fluid and the production of macrophage-derived proinflammatory mediators ([@B169]; [@B170]; [@B168]; [@B587]; [@B425]). In the subsequent phase I clinical trials, CVT-6883 was demonstrated to be safe, well tolerated, and sustainable at a once-daily chronic dosage ([@B296]). It may provide a new therapeutic option for several disease areas, including asthma, COPD, and pulmonary fibrosis.

### 3. Toreforant as an Antagonist of Histamine H4 Receptor {#s62}

Histamine has long been suspected to play a role in the pathogenesis of asthma. Among the four subtypes of histamine receptors ([@B551]), the histamine 4 receptor (H4R) is a chemotactic receptor expressed on hematopoietic cells, mast cells, and DCs ([@B464]; [@B68]; [@B251]; [@B218]; [@B130]; [@B42]; [@B217]; [@B551]; [@B284]). The results of studies testing selective H4R antagonists in animal models of asthma suggested that H4R plays a role in the pathophysiology of asthma by mediating lung function and inflammation ([@B443]; [@B604]).

Toreforant is a potent and selective H4R antagonist with a Ki of 8.4 ± 2.2 nM. The affinity for human H4R is 25-fold higher than that for histamine 3 receptor, and there was no detectable affinity for histamine 1 receptor or histamine 2 receptor. Toreforant has been found to be an anti-inflammatory reagent in mouse models of asthma and arthritis. In phase I clinical studies, toreforant was safe and well tolerated in healthy subjects ([@B603]). However, toreforant failed to provide therapeutic benefit in a recent phase II clinical study involving patients with eosinophilic asthma ([@B324]), which has brought doubts to the use of H4R antagonists in the treatment of asthma.

### 4. FX125L {#s63}

The compound FX125L was developed as a new anti-inflammatory reagent. It has gone through phase I trials and entered phase II clinical trials for the treatment of asthma and other inflammatory diseases (impact.ref.ac.uk/casestudies/CaseStudy.aspx?Id=7262). All research results on FX125L and its molecular modifications have been published as patents (patents.google.com/patent/US20090036486). The biologic target of this compound was proposed as a class A GPCR---the somatostatin receptor subtype 2, which still remains unsettled.

B. New Opportunities in G Protein--Coupled Receptor Drug Development for Asthma {#s64}
-------------------------------------------------------------------------------

GPCRs play important roles in asthma pathophysiology, which is evidenced by the wide use of GPCR-targeting drugs in the clinic and by the number of GPCR-targeting drug candidates in clinical development. Currently, significant research efforts are directed toward a better understanding of asthma pathophysiology, which may lead to the identification of new GPCR targets and novel therapeutic methods. As for drug development, recent progress in the GPCR pharmacology and structural biology provided new opportunities. Structure-based drug design has emerged as a powerful method for developing novel GPCR compounds with desired properties. GPCR-targeting therapeutic antibodies also represent a new frontier in GPCR drug discovery.

### 1. New Targets and Novel Therapeutic Methods {#s65}

There are still significant research efforts directed at identifying new GPCR targets for the treatment of asthma, especially for the endotype-guided targeted asthma therapy. A recent collaborative study from multiple research centers in the United States reported that a GPCR, the FPR2/lipoxin A~4~ receptor (ALX), and its ligands define a new endotype for severe asthma ([@B519]). FPR2/ALX exhibits unusual functional promiscuity by recognizing chemically and functionally distinct ligands to trigger different signaling pathways ([@B499]; [@B241]; [@B639]; [@B504]). It has been proposed to function as a checkpoint receptor that responds to ligands generated at different stages of inflammation to promote or resolve inflamation to keep a balanced inflammatory process. Antagonists or biased agonists of FPR2/ALX may be developed as potential therapeutics for the particular asthma endotype associated with imbalanced FPR2/ALX signaling ([@B504]). Also, the currently used leukotriene receptor antagonists only target CysLTR~1~ and block the signaling of LTC~4~ and LTD~4~, but not LTE~4~. LTE~4~ is a potent proinflammatory mediator in the airways. However, the exact receptor for LTE~4~ is still in debate ([@B475]; [@B299]). Identification of LTE~4~ receptor will allow the development of new antagonists, which may provide additional therapeutic benefits on top of current leukotriene receptor antagonists ([@B20]; [@B298]).

Identifying novel targets for asthma and the subsequent drug development is a long, ongoing effort. In the near future, novel therapeutic methods may emerge through repurposing of currently used GPCR drugs. As discussed previously, blocking detrimental *β*~2~AR signaling by *β*-blockers has been shown to reduce lung inflammation and receptor desensitization associated with chronic use of LABAs, although the potential side effect of bronchoconstriction is a concern. In this regard, *β*~2~AR negative allosteric modulators may be useful because they only dampen, not completely block, the signaling of *β*~2~AR. The therapeutic benefits of tiotropium as a LAMA also need to be further determined. Current asthma treatment guidelines only recommend tiotropium as an add-on therapy for severe asthma poorly controlled with LABA/ICS. However, it is likely that tiotropium may offer therapeutic benefits for a boutique group of asthma patients. Studies suggested its therapeutic potential for pediatric asthma patients ([@B311]; [@B202]). Also, it may offer an alternative option if LABAs are not useful due to irresponsiveness or severe side effects ([@B71]). Additional clinical studies are needed to test these ideas and clarify controversies. Continuous research into the mechanisms of GPCR signaling in asthma will bring more opportunities in drug repurposing for the treatment of asthma.

### 2. Structure-Based Drug Design {#s66}

The successful determination of GPCR structures with various drugs allows us to understand the drug action at a molecular level. These structures may serve as the basis of structure-based drug design (also known as rational drug design) to assist in the development of new drugs. Structure-based drug design is a crucial tool in preclinical drug development and has led to the delivery of several successful drugs such as Crixivan for treating AIDS ([@B102]), Tamiflu for treating influenza ([@B360]), Gleevec for treating leukemia ([@B429]), and Zelboraf for treating melanoma ([@B56]). Compounds that have been identified through the structure-based methods using recently solved GPCR crystal structures are now progressing into clinical trials ([@B119]; [@B22]; [@B104]). In the absence of crystal structures, homology modeling is the most accurate and practical tool for the predictions of new GPCR structures. The predicted homology models can yield comparable success rates in structure-based drug design with respect to the corresponding experimentally solved structures, especially for those that have been through refinement/selection with experimental data ([@B83]; [@B348]; [@B428]; [@B363]). Compounds that have been discovered through structure-based drug design using GPCR homology models have also entered clinical trials ([@B348]; [@B263]). Given the continuous rise of experimentally solved GPCR crystal structures, which also facilitate the generation of accurate homology structural models with chemically diverse ligands, it is anticipated that structure-based drug design methods will contribute increasingly to the GPCR drug development efforts, including those for asthma, to develop novel therapeutics with more desirable pharmacological properties.

### 3. G Protein--Coupled Receptor Antibodies as Therapeutics {#s67}

Although small molecules have been successfully used to target and modulate GPCRs in the treatment of many diseases, selectivity and potency are still a major challenge in GPCR drug discovery ([@B391]; [@B239]; [@B350]; [@B271]). In comparison with small molecules, GPCR antibodies may offer better specificity (e.g., by stabilizing particular conformational states of the highly dynamic receptors), restricted central nervous system penetration, new ways of regulating receptor signaling (e.g., reducing signaling by causing receptor internalization), and prolonged in vivo action ([@B266]).

Developing therapeutic antibodies for GPCRs is challenging due to many factors such as difficulties in immunization and limited surface areas in GPCRs for antibody recognition ([@B266]). To date, only two GPCR-targeting antibodies have been approved by FDA, contrasting the fact that more than 30% of small-molecule drugs target GPCRs ([@B540]). One of them is mogamulizumab targeting CCR4 ([@B11]; [@B674]; [@B315]), and the other one is erenumab targeting calcitonin gene-related receptor ([@B201]; [@B190]). Mogamulizumab and erenumab were approved by FDA in 2018 for the treatment of relapsed or refractory mycosis fungoides and Sézary disease, and the prevention of migraine, respectively. Mogamulizumab was also in phase I studies for the management/treatment of asthma ([@B480]). Multiple GPCR-targeting antibodies are currently in clinical trials or preclinical development ([@B266]). One of them is a DP2-targeting antibody, which could deplete inflammatory cells, including eosinophils, ILC2, and T~H~2 cells, and therefore may present a novel therapy for asthma ([@B262]). Preclinical studies indicated a low risk of central nervous system or gastrointestinal toxicity associated with this antibody ([@B509]).

One of the new avenues in antibody-based therapy is the development of single-chain antibodies, or nanobodies ([@B291]; [@B426]; [@B579]). Therapeutic nanobodies are derived from the heavy chain--only antibodies found in camelids. They are naturally occurring antibodies. In comparison with conventional antibodies, nanobodies are associated with several advantages, such as better solubility and tissue penetration, low immunogenicity, and high physical stability, and they can be easily produced in prokaryotic or eukaryotic host organisms ([@B236]; [@B291]; [@B320]). Currently, only one nanobody, caplacizumab, is on the market ([@B160]). Caplacizumab targets the von Willebrand factor (a clotting protein), and it was approved by FDA in 2019 for the treatment of acquired thrombotic thrombocytopenic turpura and thrombosis ([@B302], [@B303]). Therapeutic nanobodies that target GPCRs are under development, including those for the chemokine(-like) receptors CXCR4, CXCR7, CXCR2, US28, and ChemR23 ([@B278]; [@B399]; [@B62]; [@B494]; de Wit et al., 2017; [@B246]), as well as the metabotropic glutamate receptor 2 ([@B544]) and protease-activated receptor 2 (PAR2) ([@B16]; [@B487]). GPCR-targeting nanobodies have the potential to be developed as research tools, diagnostic tools, and medications for many diseases, including immune diseases, cancer, and chronic inflammatory diseases such as COPD and asthma ([@B134]).

Nanobody-based therapeutics may be particularly suitable for treating asthma and other pulmonary diseases. First, due to the unique physical properties of nanobodies such as small sizes and high solubility and stability, they can be delivered through inhalation to the lung, providing a marked advantage in drug delivery ([@B617]). Second, asthma is a complex inflammatory disease with multiple inflammatory mediators and pathways contributing to the pathogenesis of disease. The currently available antibody-based biologic agents only recognize a particular target, such as IgE or the IL-5 receptor, thus limiting their therapeutic efficacy. Because of their small size, nanobodies can be easily linked together or to other molecules as divalent or multivalent antibodies that have multiple targets ([@B579]). Multivalent nanobodies that can recognize different inflammatory mediators simultaneously may offer a better control of lung inflammation by blocking multiple inflammatory pathways.
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